AU2008262291A1 - Substituted pyrazole compounds - Google Patents

Info

Publication number

AU2008262291A1

AU2008262291A1 AU2008262291A AU2008262291A AU2008262291A1 AU 2008262291 A1 AU2008262291 A1 AU 2008262291A1 AU 2008262291 A AU2008262291 A AU 2008262291A AU 2008262291 A AU2008262291 A AU 2008262291A AU 2008262291 A1 AU2008262291 A1 AU 2008262291A1

Authority

AU

Australia

Prior art keywords

pct

disease

methyl

compound

patient

Prior art date

2007-06-11

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Abandoned

Links

• Espacenet
• Global Dossier
• Discuss

• NOIXNOMHHWGUTG-UHFFFAOYSA-N 2-[[4-[4-pyridin-4-yl-1-(2,2,2-trifluoroethyl)pyrazol-3-yl]phenoxy]methyl]quinoline Chemical class C=1C=C(OCC=2N=C3C=CC=CC3=CC=2)C=CC=1C1=NN(CC(F)(F)F)C=C1C1=CC=NC=C1 NOIXNOMHHWGUTG-UHFFFAOYSA-N 0.000 title description 2
• 238000000034 method Methods 0.000 claims description 254
• 150000001875 compounds Chemical class 0.000 claims description 224
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 193
• 201000010099 disease Diseases 0.000 claims description 175
• -1 N(R 4 ) 2 Chemical group 0.000 claims description 153
• 239000000203 mixture Substances 0.000 claims description 97
• 230000001404 mediated effect Effects 0.000 claims description 86
• 206010028980 Neoplasm Diseases 0.000 claims description 73
• 125000001072 heteroaryl group Chemical group 0.000 claims description 66
• IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 66
• 229910052739 hydrogen Inorganic materials 0.000 claims description 61
• 239000001257 hydrogen Substances 0.000 claims description 56
• 229910052757 nitrogen Inorganic materials 0.000 claims description 52
• 125000000217 alkyl group Chemical group 0.000 claims description 50
• 201000011510 cancer Diseases 0.000 claims description 44
• 125000000623 heterocyclic group Chemical group 0.000 claims description 43
• 239000000243 solution Substances 0.000 claims description 42
• 125000003118 aryl group Chemical group 0.000 claims description 32
• 125000004663 dialkyl amino group Chemical group 0.000 claims description 32
• 125000005842 heteroatom Chemical group 0.000 claims description 32
• 210000004027 cell Anatomy 0.000 claims description 31
• 239000008194 pharmaceutical composition Substances 0.000 claims description 31
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 30
• 229910052717 sulfur Chemical group 0.000 claims description 30
• 239000011593 sulfur Chemical group 0.000 claims description 30
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 29
• 229910052760 oxygen Inorganic materials 0.000 claims description 29
• 239000001301 oxygen Chemical group 0.000 claims description 29
• 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 27
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 25
• 102000002254 Glycogen Synthase Kinase 3 Human genes 0.000 claims description 24
• 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 claims description 24
• 125000003282 alkyl amino group Chemical group 0.000 claims description 24
• 230000002159 abnormal effect Effects 0.000 claims description 23
• 208000015181 infectious disease Diseases 0.000 claims description 23
• 208000027866 inflammatory disease Diseases 0.000 claims description 23
• 150000002431 hydrogen Chemical class 0.000 claims description 22
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 20
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 20
• 206010038933 Retinopathy of prematurity Diseases 0.000 claims description 19
• 208000035475 disorder Diseases 0.000 claims description 18
• 230000005764 inhibitory process Effects 0.000 claims description 18
• 150000003839 salts Chemical class 0.000 claims description 18
• 206010039073 rheumatoid arthritis Diseases 0.000 claims description 15
• 230000033115 angiogenesis Effects 0.000 claims description 14
• 125000004093 cyano group Chemical group *C#N 0.000 claims description 14
• 239000000725 suspension Substances 0.000 claims description 14
• 206010029113 Neovascularisation Diseases 0.000 claims description 13
• 208000025865 Ulcer Diseases 0.000 claims description 13
• 229910052736 halogen Inorganic materials 0.000 claims description 13
• 208000032839 leukemia Diseases 0.000 claims description 13
• 125000002950 monocyclic group Chemical group 0.000 claims description 13
• 229940002612 prodrug Drugs 0.000 claims description 13
• 239000000651 prodrug Substances 0.000 claims description 13
• 231100000397 ulcer Toxicity 0.000 claims description 13
• 201000005569 Gout Diseases 0.000 claims description 12
• 230000001684 chronic effect Effects 0.000 claims description 12
• 210000003800 pharynx Anatomy 0.000 claims description 12
• 208000010412 Glaucoma Diseases 0.000 claims description 11
• 229920002988 biodegradable polymer Polymers 0.000 claims description 11
• 239000004621 biodegradable polymer Substances 0.000 claims description 11
• 206010012601 diabetes mellitus Diseases 0.000 claims description 11
• 201000006417 multiple sclerosis Diseases 0.000 claims description 11
• 201000003142 neovascular glaucoma Diseases 0.000 claims description 11
• AHVQYHFYQWKUKB-UHFFFAOYSA-N oxan-4-amine Chemical group NC1CCOCC1 AHVQYHFYQWKUKB-UHFFFAOYSA-N 0.000 claims description 11
• 201000000306 sarcoidosis Diseases 0.000 claims description 11
• 108090000461 Aurora Kinase A Proteins 0.000 claims description 10
• 206010012689 Diabetic retinopathy Diseases 0.000 claims description 10
• 210000004369 blood Anatomy 0.000 claims description 10
• 239000008280 blood Substances 0.000 claims description 10
• 210000000481 breast Anatomy 0.000 claims description 10
• 150000002367 halogens Chemical class 0.000 claims description 10
• 206010023332 keratitis Diseases 0.000 claims description 10
• 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 10
• 239000002245 particle Substances 0.000 claims description 10
• 208000024827 Alzheimer disease Diseases 0.000 claims description 9
• 201000001320 Atherosclerosis Diseases 0.000 claims description 9
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 9
• 201000004681 Psoriasis Diseases 0.000 claims description 9
• 206010046851 Uveitis Diseases 0.000 claims description 9
• 125000003545 alkoxy group Chemical group 0.000 claims description 9
• 210000001072 colon Anatomy 0.000 claims description 9
• 230000002757 inflammatory effect Effects 0.000 claims description 9
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 9
• 210000002784 stomach Anatomy 0.000 claims description 9
• 239000000126 substance Substances 0.000 claims description 9
• 239000003981 vehicle Substances 0.000 claims description 9
• 201000009030 Carcinoma Diseases 0.000 claims description 8
• 206010011017 Corneal graft rejection Diseases 0.000 claims description 8
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 8
• 206010029260 Neuroblastoma Diseases 0.000 claims description 8
• 239000000654 additive Substances 0.000 claims description 8
• 230000000996 additive effect Effects 0.000 claims description 8
• 210000000988 bone and bone Anatomy 0.000 claims description 8
• 239000002270 dispersing agent Substances 0.000 claims description 8
• 239000003937 drug carrier Substances 0.000 claims description 8
• 210000002889 endothelial cell Anatomy 0.000 claims description 8
• 239000007788 liquid Substances 0.000 claims description 8
• 201000001441 melanoma Diseases 0.000 claims description 8
• 210000001672 ovary Anatomy 0.000 claims description 8
• 210000002307 prostate Anatomy 0.000 claims description 8
• 230000000699 topical effect Effects 0.000 claims description 8
• 208000023275 Autoimmune disease Diseases 0.000 claims description 7
• 208000024172 Cardiovascular disease Diseases 0.000 claims description 7
• 201000010208 Seminoma Diseases 0.000 claims description 7
• 239000002671 adjuvant Substances 0.000 claims description 7
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 7
• 210000000133 brain stem Anatomy 0.000 claims description 7
• 239000002775 capsule Substances 0.000 claims description 7
• 210000003169 central nervous system Anatomy 0.000 claims description 7
• 230000007850 degeneration Effects 0.000 claims description 7
• 210000004072 lung Anatomy 0.000 claims description 7
• 239000002674 ointment Substances 0.000 claims description 7
• 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 7
• 239000003755 preservative agent Substances 0.000 claims description 7
• 210000000664 rectum Anatomy 0.000 claims description 7
• 201000000980 schizophrenia Diseases 0.000 claims description 7
• 239000003826 tablet Substances 0.000 claims description 7
• 210000001550 testis Anatomy 0.000 claims description 7
• 230000029663 wound healing Effects 0.000 claims description 7
• 208000030507 AIDS Diseases 0.000 claims description 6
• 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims description 6
• 208000003200 Adenoma Diseases 0.000 claims description 6
• 206010001233 Adenoma benign Diseases 0.000 claims description 6
• 201000004384 Alopecia Diseases 0.000 claims description 6
• 206010005003 Bladder cancer Diseases 0.000 claims description 6
• 208000010667 Carcinoma of liver and intrahepatic biliary tract Diseases 0.000 claims description 6
• 206010018634 Gouty Arthritis Diseases 0.000 claims description 6
• 206010073069 Hepatic cancer Diseases 0.000 claims description 6
• 208000009889 Herpes Simplex Diseases 0.000 claims description 6
• 208000007514 Herpes zoster Diseases 0.000 claims description 6
• 208000017604 Hodgkin disease Diseases 0.000 claims description 6
• 206010061218 Inflammation Diseases 0.000 claims description 6
• 206010023347 Keratoacanthoma Diseases 0.000 claims description 6
• 208000016604 Lyme disease Diseases 0.000 claims description 6
• 208000024599 Mooren ulcer Diseases 0.000 claims description 6
• 208000010191 Osteitis Deformans Diseases 0.000 claims description 6
• 208000027868 Paget disease Diseases 0.000 claims description 6
• 206010034277 Pemphigoid Diseases 0.000 claims description 6
• 208000010362 Protozoan Infections Diseases 0.000 claims description 6
• 206010038389 Renal cancer Diseases 0.000 claims description 6
• 206010039491 Sarcoma Diseases 0.000 claims description 6
• 201000005485 Toxoplasmosis Diseases 0.000 claims description 6
• 206010064996 Ulcerative keratitis Diseases 0.000 claims description 6
• 208000013058 Weber syndrome Diseases 0.000 claims description 6
• 208000009956 adenocarcinoma Diseases 0.000 claims description 6
• 210000001367 artery Anatomy 0.000 claims description 6
• 208000006673 asthma Diseases 0.000 claims description 6
• 230000001580 bacterial effect Effects 0.000 claims description 6
• 125000002619 bicyclic group Chemical group 0.000 claims description 6
• 201000001531 bladder carcinoma Diseases 0.000 claims description 6
• 201000007293 brain stem infarction Diseases 0.000 claims description 6
• 239000000872 buffer Substances 0.000 claims description 6
• 210000003679 cervix uteri Anatomy 0.000 claims description 6
• 239000006071 cream Substances 0.000 claims description 6
• 210000003238 esophagus Anatomy 0.000 claims description 6
• 230000002538 fungal effect Effects 0.000 claims description 6
• 208000005017 glioblastoma Diseases 0.000 claims description 6
• 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 6
• 239000005556 hormone Substances 0.000 claims description 6
• 229940088597 hormone Drugs 0.000 claims description 6
• 208000026278 immune system disease Diseases 0.000 claims description 6
• 230000004054 inflammatory process Effects 0.000 claims description 6
• 208000003849 large cell carcinoma Diseases 0.000 claims description 6
• 210000002429 large intestine Anatomy 0.000 claims description 6
• 210000000867 larynx Anatomy 0.000 claims description 6
• 210000000088 lip Anatomy 0.000 claims description 6
• 201000002250 liver carcinoma Diseases 0.000 claims description 6
• 201000005249 lung adenocarcinoma Diseases 0.000 claims description 6
• 206010025135 lupus erythematosus Diseases 0.000 claims description 6
• 208000002780 macular degeneration Diseases 0.000 claims description 6
• 230000007257 malfunction Effects 0.000 claims description 6
• 208000027202 mammary Paget disease Diseases 0.000 claims description 6
• 210000000214 mouth Anatomy 0.000 claims description 6
• 230000000414 obstructive effect Effects 0.000 claims description 6
• 210000000496 pancreas Anatomy 0.000 claims description 6
• 201000010198 papillary carcinoma Diseases 0.000 claims description 6
• 201000010174 renal carcinoma Diseases 0.000 claims description 6
• 201000004700 rosacea Diseases 0.000 claims description 6
• 208000007056 sickle cell anemia Diseases 0.000 claims description 6
• 208000017520 skin disease Diseases 0.000 claims description 6
• 208000000649 small cell carcinoma Diseases 0.000 claims description 6
• 210000000813 small intestine Anatomy 0.000 claims description 6
• 206010041823 squamous cell carcinoma Diseases 0.000 claims description 6
• 230000000638 stimulation Effects 0.000 claims description 6
• 239000000829 suppository Substances 0.000 claims description 6
• 239000004094 surface-active agent Substances 0.000 claims description 6
• 239000000375 suspending agent Substances 0.000 claims description 6
• 208000011580 syndromic disease Diseases 0.000 claims description 6
• 208000006379 syphilis Diseases 0.000 claims description 6
• 230000009885 systemic effect Effects 0.000 claims description 6
• 210000001685 thyroid gland Anatomy 0.000 claims description 6
• 210000002105 tongue Anatomy 0.000 claims description 6
• 208000010576 undifferentiated carcinoma Diseases 0.000 claims description 6
• 208000010570 urinary bladder carcinoma Diseases 0.000 claims description 6
• 230000002792 vascular Effects 0.000 claims description 6
• 210000003462 vein Anatomy 0.000 claims description 6
• 206010001257 Adenoviral conjunctivitis Diseases 0.000 claims description 5
• 206010003645 Atopy Diseases 0.000 claims description 5
• 102000004000 Aurora Kinase A Human genes 0.000 claims description 5
• 208000002691 Choroiditis Diseases 0.000 claims description 5
• 206010012289 Dementia Diseases 0.000 claims description 5
• 206010013774 Dry eye Diseases 0.000 claims description 5
• 208000016974 Eales' disease Diseases 0.000 claims description 5
• 201000002563 Histoplasmosis Diseases 0.000 claims description 5
• 208000023105 Huntington disease Diseases 0.000 claims description 5
• 206010020751 Hypersensitivity Diseases 0.000 claims description 5
• 206010020880 Hypertrophy Diseases 0.000 claims description 5
• 206010051151 Hyperviscosity syndrome Diseases 0.000 claims description 5
• 208000007766 Kaposi sarcoma Diseases 0.000 claims description 5
• 206010025412 Macular dystrophy congenital Diseases 0.000 claims description 5
• 208000012902 Nervous system disease Diseases 0.000 claims description 5
• 208000025966 Neurological disease Diseases 0.000 claims description 5
• 208000018737 Parkinson disease Diseases 0.000 claims description 5
• 208000003971 Posterior uveitis Diseases 0.000 claims description 5
• 201000002154 Pterygium Diseases 0.000 claims description 5
• 206010038848 Retinal detachment Diseases 0.000 claims description 5
• 206010038910 Retinitis Diseases 0.000 claims description 5
• 206010039705 Scleritis Diseases 0.000 claims description 5
• 208000010011 Vitamin A Deficiency Diseases 0.000 claims description 5
• 206010047663 Vitritis Diseases 0.000 claims description 5
• 230000007815 allergy Effects 0.000 claims description 5
• 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 5
• 239000000839 emulsion Substances 0.000 claims description 5
• 208000021373 epidemic keratoconjunctivitis Diseases 0.000 claims description 5
• 239000000796 flavoring agent Substances 0.000 claims description 5
• 230000003676 hair loss Effects 0.000 claims description 5
• 208000013653 hyalitis Diseases 0.000 claims description 5
• 125000001041 indolyl group Chemical group 0.000 claims description 5
• 208000014674 injury Diseases 0.000 claims description 5
• 208000028867 ischemia Diseases 0.000 claims description 5
• 230000035984 keratolysis Effects 0.000 claims description 5
• 230000002197 limbic effect Effects 0.000 claims description 5
• 150000002632 lipids Chemical class 0.000 claims description 5
• 239000000314 lubricant Substances 0.000 claims description 5
• 208000001491 myopia Diseases 0.000 claims description 5
• 230000004379 myopia Effects 0.000 claims description 5
• 208000015122 neurodegenerative disease Diseases 0.000 claims description 5
• 239000000843 powder Substances 0.000 claims description 5
• 230000002335 preservative effect Effects 0.000 claims description 5
• 230000010410 reperfusion Effects 0.000 claims description 5
• 230000004264 retinal detachment Effects 0.000 claims description 5
• 201000006476 shipyard eye Diseases 0.000 claims description 5
• 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 5
• 208000030901 thyroid gland follicular carcinoma Diseases 0.000 claims description 5
• 230000008733 trauma Effects 0.000 claims description 5
• 201000007790 vitelliform macular dystrophy Diseases 0.000 claims description 5
• 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 4
• 102100028187 ATP-binding cassette sub-family C member 6 Human genes 0.000 claims description 4
• 108010010803 Gelatin Proteins 0.000 claims description 4
• 208000004788 Pars Planitis Diseases 0.000 claims description 4
• 201000004613 Pseudoxanthoma elasticum Diseases 0.000 claims description 4
• 208000018656 Terrien marginal degeneration Diseases 0.000 claims description 4
• 206010052779 Transplant rejections Diseases 0.000 claims description 4
• 239000000443 aerosol Substances 0.000 claims description 4
• 239000003963 antioxidant agent Substances 0.000 claims description 4
• 230000003078 antioxidant effect Effects 0.000 claims description 4
• 235000006708 antioxidants Nutrition 0.000 claims description 4
• 239000011230 binding agent Substances 0.000 claims description 4
• 239000006260 foam Substances 0.000 claims description 4
• 235000013355 food flavoring agent Nutrition 0.000 claims description 4
• 239000000499 gel Substances 0.000 claims description 4
• 239000008273 gelatin Substances 0.000 claims description 4
• 229920000159 gelatin Polymers 0.000 claims description 4
• 235000019322 gelatine Nutrition 0.000 claims description 4
• 235000011852 gelatine desserts Nutrition 0.000 claims description 4
• 235000011187 glycerol Nutrition 0.000 claims description 4
• 239000008187 granular material Substances 0.000 claims description 4
• 239000003701 inert diluent Substances 0.000 claims description 4
• 239000007937 lozenge Substances 0.000 claims description 4
• 239000002324 mouth wash Substances 0.000 claims description 4
• 229940051866 mouthwash Drugs 0.000 claims description 4
• DILRJUIACXKSQE-UHFFFAOYSA-N n',n'-dimethylethane-1,2-diamine Chemical group CN(C)CCN DILRJUIACXKSQE-UHFFFAOYSA-N 0.000 claims description 4
• 230000004770 neurodegeneration Effects 0.000 claims description 4
• 230000000926 neurological effect Effects 0.000 claims description 4
• 235000010603 pastilles Nutrition 0.000 claims description 4
• 208000023558 pseudoxanthoma elasticum (inherited or acquired) Diseases 0.000 claims description 4
• 239000007921 spray Substances 0.000 claims description 4
• 239000002562 thickening agent Substances 0.000 claims description 4
• GOWUDHPKGOIDIX-UHFFFAOYSA-N 2-(4-methyl-1-piperazinyl)ethanamine Chemical group CN1CCN(CCN)CC1 GOWUDHPKGOIDIX-UHFFFAOYSA-N 0.000 claims description 3
• KOHBEDRJXKOYHL-UHFFFAOYSA-N 2-methoxy-n-methylethanamine Chemical group CNCCOC KOHBEDRJXKOYHL-UHFFFAOYSA-N 0.000 claims description 3
• 208000026935 allergic disease Diseases 0.000 claims description 3
• RWIVICVCHVMHMU-UHFFFAOYSA-N n-aminoethylmorpholine Chemical group NCCN1CCOCC1 RWIVICVCHVMHMU-UHFFFAOYSA-N 0.000 claims description 3
• 125000006655 (C3-C8) heteroaryl group Chemical group 0.000 claims description 2
• ASUDFOJKTJLAIK-UHFFFAOYSA-N 2-methoxyethanamine Chemical group COCCN ASUDFOJKTJLAIK-UHFFFAOYSA-N 0.000 claims description 2
• PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 claims 1
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 261
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 194
• 238000005481 NMR spectroscopy Methods 0.000 description 139
• 238000004128 high performance liquid chromatography Methods 0.000 description 113
• 235000019439 ethyl acetate Nutrition 0.000 description 88
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 69
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 68
• 238000006243 chemical reaction Methods 0.000 description 47
• 239000007787 solid Substances 0.000 description 46
• 239000011541 reaction mixture Substances 0.000 description 45
• 125000001931 aliphatic group Chemical group 0.000 description 42
• 239000003112 inhibitor Substances 0.000 description 38
• 238000011282 treatment Methods 0.000 description 33
• 230000000694 effects Effects 0.000 description 32
• MISVBCMQSJUHMH-UHFFFAOYSA-N pyrimidine-4,6-diamine Chemical compound NC1=CC(N)=NC=N1 MISVBCMQSJUHMH-UHFFFAOYSA-N 0.000 description 26
• 239000000047 product Substances 0.000 description 25
• 230000002401 inhibitory effect Effects 0.000 description 24
• JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical group CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 23
• 238000003556 assay Methods 0.000 description 22
• 125000001424 substituent group Chemical group 0.000 description 22
• 101100335081 Mus musculus Flt3 gene Proteins 0.000 description 19
• FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 19
• 239000011734 sodium Substances 0.000 description 19
• 238000005160 1H NMR spectroscopy Methods 0.000 description 18
• 108091000080 Phosphotransferase Proteins 0.000 description 18
• 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 18
• 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 18
• 239000002585 base Substances 0.000 description 18
• 239000012267 brine Substances 0.000 description 18
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 18
• 102000020233 phosphotransferase Human genes 0.000 description 18
• OYRRZWATULMEPF-UHFFFAOYSA-N pyrimidin-4-amine Chemical compound NC1=CC=NC=N1 OYRRZWATULMEPF-UHFFFAOYSA-N 0.000 description 18
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 18
• 239000004698 Polyethylene Substances 0.000 description 17
• 101150001535 SRC gene Proteins 0.000 description 17
• 239000002904 solvent Substances 0.000 description 17
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 16
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
• 239000012472 biological sample Substances 0.000 description 16
• 239000003795 chemical substances by application Substances 0.000 description 16
• 239000005441 aurora Substances 0.000 description 15
• 229910052799 carbon Inorganic materials 0.000 description 15
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
• 239000003814 drug Substances 0.000 description 14
• 101150028321 Lck gene Proteins 0.000 description 13
• CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 13
• 238000004440 column chromatography Methods 0.000 description 13
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
• 101100268648 Mus musculus Abl1 gene Proteins 0.000 description 12
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
• 239000003153 chemical reaction reagent Substances 0.000 description 12
• 238000009472 formulation Methods 0.000 description 12
• FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 12
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 11
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
• 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 11
• 108091008611 Protein Kinase B Proteins 0.000 description 11
• 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 11
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 11
• 230000002939 deleterious effect Effects 0.000 description 11
• 229940079593 drug Drugs 0.000 description 11
• 229920006395 saturated elastomer Polymers 0.000 description 11
• 239000012043 crude product Substances 0.000 description 10
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 10
• 238000012360 testing method Methods 0.000 description 10
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
• 101100439046 Caenorhabditis elegans cdk-2 gene Proteins 0.000 description 8
• 102000004190 Enzymes Human genes 0.000 description 8
• 108090000790 Enzymes Proteins 0.000 description 8
• MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 8
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 8
• 102000001253 Protein Kinase Human genes 0.000 description 8
• 150000001412 amines Chemical class 0.000 description 8
• 229940088598 enzyme Drugs 0.000 description 8
• 229940043355 kinase inhibitor Drugs 0.000 description 8
• 230000011278 mitosis Effects 0.000 description 8
• 230000008569 process Effects 0.000 description 8
• 108060006633 protein kinase Proteins 0.000 description 8
• 210000003491 skin Anatomy 0.000 description 8
• PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 7
• FYTLHYRDGXRYEY-UHFFFAOYSA-N 5-Methyl-3-pyrazolamine Chemical compound CC=1C=C(N)NN=1 FYTLHYRDGXRYEY-UHFFFAOYSA-N 0.000 description 7
• 108700015928 Mitogen-activated protein kinase 13 Proteins 0.000 description 7
• 125000004429 atom Chemical group 0.000 description 7
• XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 7
• 210000000349 chromosome Anatomy 0.000 description 7
• 229940113088 dimethylacetamide Drugs 0.000 description 7
• 239000002552 dosage form Substances 0.000 description 7
• 230000026731 phosphorylation Effects 0.000 description 7
• 238000006366 phosphorylation reaction Methods 0.000 description 7
• 239000003909 protein kinase inhibitor Substances 0.000 description 7
• 108090000623 proteins and genes Proteins 0.000 description 7
• 125000006413 ring segment Chemical group 0.000 description 7
• 238000003756 stirring Methods 0.000 description 7
• DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 6
• FNOPVHJQTDCIGI-UHFFFAOYSA-N 6-chloro-2-(1-methylindol-2-yl)-n-(5-methyl-1h-pyrazol-3-yl)pyrimidin-4-amine Chemical compound N1C(C)=CC(NC=2N=C(N=C(Cl)C=2)C=2N(C3=CC=CC=C3C=2)C)=N1 FNOPVHJQTDCIGI-UHFFFAOYSA-N 0.000 description 6
• ZYSRCGLTFICAEO-UHFFFAOYSA-N 6-chloro-n-(5-methyl-1h-pyrazol-3-yl)-2-phenylpyrimidin-4-amine Chemical compound N1N=C(C)C=C1NC1=CC(Cl)=NC(C=2C=CC=CC=2)=N1 ZYSRCGLTFICAEO-UHFFFAOYSA-N 0.000 description 6
• WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
• WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
• 108010033040 Histones Proteins 0.000 description 6
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
• WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 6
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
• 239000002253 acid Substances 0.000 description 6
• 150000001408 amides Chemical class 0.000 description 6
• 229960001484 edetic acid Drugs 0.000 description 6
• 125000005843 halogen group Chemical group 0.000 description 6
• 230000002140 halogenating effect Effects 0.000 description 6
• 238000011534 incubation Methods 0.000 description 6
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 6
• 125000005647 linker group Chemical group 0.000 description 6
• UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 6
• 239000011654 magnesium acetate Substances 0.000 description 6
• 235000011285 magnesium acetate Nutrition 0.000 description 6
• 229940069446 magnesium acetate Drugs 0.000 description 6
• 229920000642 polymer Polymers 0.000 description 6
• 238000002360 preparation method Methods 0.000 description 6
• 125000000719 pyrrolidinyl group Chemical group 0.000 description 6
• 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 5
• ZJARBPALAUYPDP-UHFFFAOYSA-N 4-(oxan-4-yl)-1H-pyrimidine-4,6-diamine Chemical compound O1CCC(CC1)C1(C=C(N=CN1)N)N ZJARBPALAUYPDP-UHFFFAOYSA-N 0.000 description 5
• 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 5
• 102100032311 Aurora kinase A Human genes 0.000 description 5
• 102000003989 Aurora kinases Human genes 0.000 description 5
• 108090000433 Aurora kinases Proteins 0.000 description 5
• 201000009273 Endometriosis Diseases 0.000 description 5
• YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
• 241000282412 Homo Species 0.000 description 5
• 125000004453 alkoxycarbonyl group Chemical group 0.000 description 5
• 125000001118 alkylidene group Chemical group 0.000 description 5
• 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 5
• 239000000969 carrier Substances 0.000 description 5
• 238000010168 coupling process Methods 0.000 description 5
• 230000021953 cytokinesis Effects 0.000 description 5
• 230000002357 endometrial effect Effects 0.000 description 5
• 230000012010 growth Effects 0.000 description 5
• 125000001188 haloalkyl group Chemical group 0.000 description 5
• 239000010410 layer Substances 0.000 description 5
• 125000002757 morpholinyl group Chemical group 0.000 description 5
• 125000006574 non-aromatic ring group Chemical group 0.000 description 5
• 125000004193 piperazinyl group Chemical group 0.000 description 5
• 125000003386 piperidinyl group Chemical group 0.000 description 5
• 108090000765 processed proteins & peptides Proteins 0.000 description 5
• 102000004169 proteins and genes Human genes 0.000 description 5
• 125000000714 pyrimidinyl group Chemical group 0.000 description 5
• 230000002829 reductive effect Effects 0.000 description 5
• 238000003786 synthesis reaction Methods 0.000 description 5
• IUHPWAOKRDQEIH-UHFFFAOYSA-N 2-(1-benzofuran-2-yl)-6-chloro-n-(5-methyl-1h-pyrazol-3-yl)pyrimidin-4-amine Chemical compound N1C(C)=CC(NC=2N=C(N=C(Cl)C=2)C=2OC3=CC=CC=C3C=2)=N1 IUHPWAOKRDQEIH-UHFFFAOYSA-N 0.000 description 4
• ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 4
• YCIPQJTZJGUXND-UHFFFAOYSA-N Aglaia odorata Alkaloid Natural products C1=CC(OC)=CC=C1C1(C(C=2C(=O)N3CCCC3=NC=22)C=3C=CC=CC=3)C2(O)C2=C(OC)C=C(OC)C=C2O1 YCIPQJTZJGUXND-UHFFFAOYSA-N 0.000 description 4
• 108010077544 Chromatin Proteins 0.000 description 4
• 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 4
• 102000014150 Interferons Human genes 0.000 description 4
• 108010050904 Interferons Proteins 0.000 description 4
• 241001465754 Metazoa Species 0.000 description 4
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
• 229940122924 Src inhibitor Drugs 0.000 description 4
• 125000003342 alkenyl group Chemical group 0.000 description 4
• 125000003418 alkyl amino alkoxy group Chemical group 0.000 description 4
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 4
• 229940059260 amidate Drugs 0.000 description 4
• 125000006615 aromatic heterocyclic group Chemical group 0.000 description 4
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
• 230000015572 biosynthetic process Effects 0.000 description 4
• 210000000625 blastula Anatomy 0.000 description 4
• 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 4
• 125000004452 carbocyclyl group Chemical group 0.000 description 4
• 210000003483 chromatin Anatomy 0.000 description 4
• 239000003246 corticosteroid Substances 0.000 description 4
• 229960001334 corticosteroids Drugs 0.000 description 4
• ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 4
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 4
• 125000004984 dialkylaminoalkoxy group Chemical group 0.000 description 4
• 125000004473 dialkylaminocarbonyl group Chemical group 0.000 description 4
• 150000002148 esters Chemical class 0.000 description 4
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
• 229910052731 fluorine Inorganic materials 0.000 description 4
• 125000004438 haloalkoxy group Chemical group 0.000 description 4
• 125000001475 halogen functional group Chemical group 0.000 description 4
• 238000002513 implantation Methods 0.000 description 4
• 125000002249 indol-2-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([*])=C([H])C2=C1[H] 0.000 description 4
• 229940047124 interferons Drugs 0.000 description 4
• 239000000543 intermediate Substances 0.000 description 4
• 229910052744 lithium Inorganic materials 0.000 description 4
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
• 239000002105 nanoparticle Substances 0.000 description 4
• 150000002825 nitriles Chemical class 0.000 description 4
• 230000016087 ovulation Effects 0.000 description 4
• RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 4
• NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Substances [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 4
• 238000000746 purification Methods 0.000 description 4
• VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical compound OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 description 4
• 230000009467 reduction Effects 0.000 description 4
• 238000006722 reduction reaction Methods 0.000 description 4
• 239000000377 silicon dioxide Substances 0.000 description 4
• 239000011780 sodium chloride Substances 0.000 description 4
• 235000009518 sodium iodide Nutrition 0.000 description 4
• 102000009076 src-Family Kinases Human genes 0.000 description 4
• 108010087686 src-Family Kinases Proteins 0.000 description 4
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
• 238000004809 thin layer chromatography Methods 0.000 description 4
• 125000006714 (C3-C10) heterocyclyl group Chemical group 0.000 description 3
• APWRZPQBPCAXFP-UHFFFAOYSA-N 1-(1-oxo-2H-isoquinolin-5-yl)-5-(trifluoromethyl)-N-[2-(trifluoromethyl)pyridin-4-yl]pyrazole-4-carboxamide Chemical compound O=C1NC=CC2=C(C=CC=C12)N1N=CC(=C1C(F)(F)F)C(=O)NC1=CC(=NC=C1)C(F)(F)F APWRZPQBPCAXFP-UHFFFAOYSA-N 0.000 description 3
• ZQGAXHXHVKVERC-UHFFFAOYSA-N 1-benzofuran-2-carbonitrile Chemical compound C1=CC=C2OC(C#N)=CC2=C1 ZQGAXHXHVKVERC-UHFFFAOYSA-N 0.000 description 3
• PDECXGQFPNZGGZ-UHFFFAOYSA-N 1-benzofuran-2-carboximidamide Chemical compound C1=CC=C2OC(C(=N)N)=CC2=C1 PDECXGQFPNZGGZ-UHFFFAOYSA-N 0.000 description 3
• JMASJMJGQFASFK-UHFFFAOYSA-N 1-methylindole-2-carboximidamide Chemical compound C1=CC=C2N(C)C(C(N)=N)=CC2=C1 JMASJMJGQFASFK-UHFFFAOYSA-N 0.000 description 3
• LYWIKHXVKXUBTP-UHFFFAOYSA-N 2-(1-benzofuran-2-yl)-1h-pyrimidine-4,6-dione Chemical compound N1C(=O)CC(=O)N=C1C1=CC2=CC=CC=C2O1 LYWIKHXVKXUBTP-UHFFFAOYSA-N 0.000 description 3
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
• XJPZKYIHCLDXST-UHFFFAOYSA-N 4,6-dichloropyrimidine Chemical compound ClC1=CC(Cl)=NC=N1 XJPZKYIHCLDXST-UHFFFAOYSA-N 0.000 description 3
• 108090000749 Aurora kinase B Proteins 0.000 description 3
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 3
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
• 208000031953 Hereditary hemorrhagic telangiectasia Diseases 0.000 description 3
• 102000006947 Histones Human genes 0.000 description 3
• WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 3
• 102000000589 Interleukin-1 Human genes 0.000 description 3
• 108010002352 Interleukin-1 Proteins 0.000 description 3
• 239000007993 MOPS buffer Substances 0.000 description 3
• 206010027476 Metastases Diseases 0.000 description 3
• 108700020796 Oncogene Proteins 0.000 description 3
• 229910019142 PO4 Inorganic materials 0.000 description 3
• KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
• 102000000763 Survivin Human genes 0.000 description 3
• 108010002687 Survivin Proteins 0.000 description 3
• 125000004457 alkyl amino carbonyl group Chemical group 0.000 description 3
• 125000005195 alkyl amino carbonyloxy group Chemical group 0.000 description 3
• 125000004448 alkyl carbonyl group Chemical group 0.000 description 3
• 150000001413 amino acids Chemical class 0.000 description 3
• 230000031016 anaphase Effects 0.000 description 3
• 125000003710 aryl alkyl group Chemical group 0.000 description 3
• CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical compound N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 description 3
• 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 3
• JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 3
• 125000002618 bicyclic heterocycle group Chemical group 0.000 description 3
• 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 description 3
• 210000004204 blood vessel Anatomy 0.000 description 3
• 229910052794 bromium Inorganic materials 0.000 description 3
• 125000002837 carbocyclic group Chemical group 0.000 description 3
• 150000001721 carbon Chemical group 0.000 description 3
• 239000003054 catalyst Substances 0.000 description 3
• 230000010261 cell growth Effects 0.000 description 3
• 230000036755 cellular response Effects 0.000 description 3
• 229920002678 cellulose Polymers 0.000 description 3
• 235000010980 cellulose Nutrition 0.000 description 3
• 229910052801 chlorine Inorganic materials 0.000 description 3
• 238000004587 chromatography analysis Methods 0.000 description 3
• 230000008878 coupling Effects 0.000 description 3
• 238000005859 coupling reaction Methods 0.000 description 3
• 125000004122 cyclic group Chemical group 0.000 description 3
• 125000000753 cycloalkyl group Chemical group 0.000 description 3
• 229960004397 cyclophosphamide Drugs 0.000 description 3
• 125000005202 dialkylaminocarbonyloxy group Chemical group 0.000 description 3
• 239000003085 diluting agent Substances 0.000 description 3
• BEPAFCGSDWSTEL-UHFFFAOYSA-N dimethyl malonate Chemical compound COC(=O)CC(=O)OC BEPAFCGSDWSTEL-UHFFFAOYSA-N 0.000 description 3
• 238000001035 drying Methods 0.000 description 3
• 239000000284 extract Substances 0.000 description 3
• 239000007789 gas Substances 0.000 description 3
• 210000001035 gastrointestinal tract Anatomy 0.000 description 3
• 201000011066 hemangioma Diseases 0.000 description 3
• 125000004475 heteroaralkyl group Chemical group 0.000 description 3
• 125000004356 hydroxy functional group Chemical group O* 0.000 description 3
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 3
• 229910052740 iodine Inorganic materials 0.000 description 3
• 210000003734 kidney Anatomy 0.000 description 3
• 238000000021 kinase assay Methods 0.000 description 3
• 230000000670 limiting effect Effects 0.000 description 3
• 238000004519 manufacturing process Methods 0.000 description 3
• 239000000463 material Substances 0.000 description 3
• 230000021121 meiosis Effects 0.000 description 3
• 230000005906 menstruation Effects 0.000 description 3
• 230000009401 metastasis Effects 0.000 description 3
• 230000004048 modification Effects 0.000 description 3
• 238000012986 modification Methods 0.000 description 3
• 239000003921 oil Substances 0.000 description 3
• 235000019198 oils Nutrition 0.000 description 3
• 239000012044 organic layer Substances 0.000 description 3
• 230000037361 pathway Effects 0.000 description 3
• 235000019271 petrolatum Nutrition 0.000 description 3
• 239000000546 pharmaceutical excipient Substances 0.000 description 3
• 235000021317 phosphate Nutrition 0.000 description 3
• 239000003757 phosphotransferase inhibitor Substances 0.000 description 3
• 229920001223 polyethylene glycol Polymers 0.000 description 3
• 229920001184 polypeptide Polymers 0.000 description 3
• 102000004196 processed proteins & peptides Human genes 0.000 description 3
• 230000002062 proliferating effect Effects 0.000 description 3
• 125000003226 pyrazolyl group Chemical group 0.000 description 3
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
• 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 3
• 238000012552 review Methods 0.000 description 3
• 238000003345 scintillation counting Methods 0.000 description 3
• 238000013207 serial dilution Methods 0.000 description 3
• 238000006467 substitution reaction Methods 0.000 description 3
• 239000000758 substrate Substances 0.000 description 3
• 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 3
• 229940124597 therapeutic agent Drugs 0.000 description 3
• 210000001519 tissue Anatomy 0.000 description 3
• 239000010936 titanium Substances 0.000 description 3
• DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
• PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
• 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 2
• ZGYIXVSQHOKQRZ-COIATFDQSA-N (e)-n-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-[(3s)-oxolan-3-yl]oxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide Chemical compound N#CC1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZGYIXVSQHOKQRZ-COIATFDQSA-N 0.000 description 2
• MOWXJLUYGFNTAL-DEOSSOPVSA-N (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol Chemical compound N1=NC(OC)=CC=C1[C@@H](O)C1=CC(C=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C(F)C=C1Cl MOWXJLUYGFNTAL-DEOSSOPVSA-N 0.000 description 2
• IBNGPIOSWCMJGG-UHFFFAOYSA-N 1-methylindole-2-carbaldehyde Chemical compound C1=CC=C2N(C)C(C=O)=CC2=C1 IBNGPIOSWCMJGG-UHFFFAOYSA-N 0.000 description 2
• JOCOGYNDZDYYOS-UHFFFAOYSA-N 1-methylindole-2-carbonitrile Chemical compound C1=CC=C2N(C)C(C#N)=CC2=C1 JOCOGYNDZDYYOS-UHFFFAOYSA-N 0.000 description 2
• 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 2
• JVVRJMXHNUAPHW-UHFFFAOYSA-N 1h-pyrazol-5-amine Chemical compound NC=1C=CNN=1 JVVRJMXHNUAPHW-UHFFFAOYSA-N 0.000 description 2
• HFAYWAUCHUMJMH-UHFFFAOYSA-N 1h-pyrimidine-4,6-dione Chemical compound O=C1CC(=O)N=CN1 HFAYWAUCHUMJMH-UHFFFAOYSA-N 0.000 description 2
• DPVIABCMTHHTGB-UHFFFAOYSA-N 2,4,6-trichloropyrimidine Chemical compound ClC1=CC(Cl)=NC(Cl)=N1 DPVIABCMTHHTGB-UHFFFAOYSA-N 0.000 description 2
• GPLQMOQXDNVHJH-UHFFFAOYSA-N 2-(1-benzofuran-2-yl)-4,6-dichloropyrimidine Chemical compound ClC1=CC(Cl)=NC(C=2OC3=CC=CC=C3C=2)=N1 GPLQMOQXDNVHJH-UHFFFAOYSA-N 0.000 description 2
• XRNXIZBUGWLXEU-UHFFFAOYSA-N 2-(4,6-dichloropyrimidin-2-yl)-1-methylindole Chemical compound C=1C2=CC=CC=C2N(C)C=1C1=NC(Cl)=CC(Cl)=N1 XRNXIZBUGWLXEU-UHFFFAOYSA-N 0.000 description 2
• ADDZHRRCUWNSCS-UHFFFAOYSA-N 2-Benzofurancarboxaldehyde Chemical compound C1=CC=C2OC(C=O)=CC2=C1 ADDZHRRCUWNSCS-UHFFFAOYSA-N 0.000 description 2
• IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 2
• IOOMXAQUNPWDLL-UHFFFAOYSA-N 2-[6-(diethylamino)-3-(diethyliminiumyl)-3h-xanthen-9-yl]-5-sulfobenzene-1-sulfonate Chemical compound C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S(O)(=O)=O)C=C1S([O-])(=O)=O IOOMXAQUNPWDLL-UHFFFAOYSA-N 0.000 description 2
• 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 2
• HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 2
• WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 2
• SRVXSISGYBMIHR-UHFFFAOYSA-N 3-[3-[3-(2-amino-2-oxoethyl)phenyl]-5-chlorophenyl]-3-(5-methyl-1,3-thiazol-2-yl)propanoic acid Chemical compound S1C(C)=CN=C1C(CC(O)=O)C1=CC(Cl)=CC(C=2C=C(CC(N)=O)C=CC=2)=C1 SRVXSISGYBMIHR-UHFFFAOYSA-N 0.000 description 2
• ORCFLJAMBJPDEP-UHFFFAOYSA-N 4-(5-methyl-1H-pyrazol-3-yl)-2-phenyl-1H-pyrimidine-4,6-diamine Chemical compound CC1=CC(=NN1)C1(C=C(N=C(N1)C1=CC=CC=C1)N)N ORCFLJAMBJPDEP-UHFFFAOYSA-N 0.000 description 2
• YFCIFWOJYYFDQP-PTWZRHHISA-N 4-[3-amino-6-[(1S,3S,4S)-3-fluoro-4-hydroxycyclohexyl]pyrazin-2-yl]-N-[(1S)-1-(3-bromo-5-fluorophenyl)-2-(methylamino)ethyl]-2-fluorobenzamide Chemical compound CNC[C@@H](NC(=O)c1ccc(cc1F)-c1nc(cnc1N)[C@H]1CC[C@H](O)[C@@H](F)C1)c1cc(F)cc(Br)c1 YFCIFWOJYYFDQP-PTWZRHHISA-N 0.000 description 2
• KCBWAFJCKVKYHO-UHFFFAOYSA-N 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-[[4-[1-propan-2-yl-4-(trifluoromethyl)imidazol-2-yl]phenyl]methyl]pyrazolo[3,4-d]pyrimidine Chemical compound C1(CC1)C1=NC=NC(=C1C1=NC=C2C(=N1)N(N=C2)CC1=CC=C(C=C1)C=1N(C=C(N=1)C(F)(F)F)C(C)C)OC KCBWAFJCKVKYHO-UHFFFAOYSA-N 0.000 description 2
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
• 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
• 229940126638 Akt inhibitor Drugs 0.000 description 2
• 201000000736 Amenorrhea Diseases 0.000 description 2
• 206010001928 Amenorrhoea Diseases 0.000 description 2
• NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
• XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
• 102000004228 Aurora kinase B Human genes 0.000 description 2
• 206010006187 Breast cancer Diseases 0.000 description 2
• 208000026310 Breast neoplasm Diseases 0.000 description 2
• 208000009043 Chemical Burns Diseases 0.000 description 2
• 206010009944 Colon cancer Diseases 0.000 description 2
• 208000035473 Communicable disease Diseases 0.000 description 2
• 229920002261 Corn starch Polymers 0.000 description 2
• 102000000578 Cyclin-Dependent Kinase Inhibitor p21 Human genes 0.000 description 2
• 108010016788 Cyclin-Dependent Kinase Inhibitor p21 Proteins 0.000 description 2
• 208000031124 Dementia Alzheimer type Diseases 0.000 description 2
• IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
• QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
• GISRWBROCYNDME-PELMWDNLSA-N F[C@H]1[C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)C Chemical compound F[C@H]1[C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)C GISRWBROCYNDME-PELMWDNLSA-N 0.000 description 2
• 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
• 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
• 229920002527 Glycogen Polymers 0.000 description 2
• 239000007995 HEPES buffer Substances 0.000 description 2
• SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
• UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 2
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
• 206010025323 Lymphomas Diseases 0.000 description 2
• AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 2
• 201000004404 Neurofibroma Diseases 0.000 description 2
• IDRGFNPZDVBSSE-UHFFFAOYSA-N OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F Chemical compound OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F IDRGFNPZDVBSSE-UHFFFAOYSA-N 0.000 description 2
• 101100338491 Oryza sativa subsp. japonica HCT1 gene Proteins 0.000 description 2
• 208000001132 Osteoporosis Diseases 0.000 description 2
• 206010033128 Ovarian cancer Diseases 0.000 description 2
• 239000004264 Petrolatum Substances 0.000 description 2
• 239000002202 Polyethylene glycol Substances 0.000 description 2
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
• 206010060862 Prostate cancer Diseases 0.000 description 2
• 206010037649 Pyogenic granuloma Diseases 0.000 description 2
• WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 2
• 101100495309 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CDH1 gene Proteins 0.000 description 2
• 208000006011 Stroke Diseases 0.000 description 2
• 238000006069 Suzuki reaction reaction Methods 0.000 description 2
• 206010042971 T-cell lymphoma Diseases 0.000 description 2
• 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
• YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
• 229910021626 Tin(II) chloride Inorganic materials 0.000 description 2
• 241000390203 Trachoma Species 0.000 description 2
• HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
• 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
• 241000269370 Xenopus <genus> Species 0.000 description 2
• 210000001015 abdomen Anatomy 0.000 description 2
• 238000002835 absorbance Methods 0.000 description 2
• 208000004064 acoustic neuroma Diseases 0.000 description 2
• 230000004913 activation Effects 0.000 description 2
• 239000004480 active ingredient Substances 0.000 description 2
• 230000001154 acute effect Effects 0.000 description 2
• 150000001299 aldehydes Chemical class 0.000 description 2
• 125000004183 alkoxy alkyl group Chemical group 0.000 description 2
• 125000000304 alkynyl group Chemical group 0.000 description 2
• PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
• 231100000540 amenorrhea Toxicity 0.000 description 2
• 150000001409 amidines Chemical class 0.000 description 2
• 229940024606 amino acid Drugs 0.000 description 2
• 125000003277 amino group Chemical group 0.000 description 2
• 230000002491 angiogenic effect Effects 0.000 description 2
• 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 description 2
• 239000007864 aqueous solution Substances 0.000 description 2
• 239000007900 aqueous suspension Substances 0.000 description 2
• 125000005160 aryl oxy alkyl group Chemical group 0.000 description 2
• 239000012131 assay buffer Substances 0.000 description 2
• LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 2
• 229960002170 azathioprine Drugs 0.000 description 2
• 125000005605 benzo group Chemical group 0.000 description 2
• 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 2
• 235000019445 benzyl alcohol Nutrition 0.000 description 2
• 229960000397 bevacizumab Drugs 0.000 description 2
• 230000036765 blood level Effects 0.000 description 2
• 230000037396 body weight Effects 0.000 description 2
• 238000009835 boiling Methods 0.000 description 2
• 210000001185 bone marrow Anatomy 0.000 description 2
• QARVLSVVCXYDNA-UHFFFAOYSA-N bromobenzene Chemical compound BrC1=CC=CC=C1 QARVLSVVCXYDNA-UHFFFAOYSA-N 0.000 description 2
• 239000012830 cancer therapeutic Substances 0.000 description 2
• 125000004432 carbon atom Chemical group C* 0.000 description 2
• 239000001768 carboxy methyl cellulose Substances 0.000 description 2
• 230000024321 chromosome segregation Effects 0.000 description 2
• 239000012141 concentrate Substances 0.000 description 2
• 238000009833 condensation Methods 0.000 description 2
• 230000005494 condensation Effects 0.000 description 2
• 239000008120 corn starch Substances 0.000 description 2
• 229940099112 cornstarch Drugs 0.000 description 2
• 235000001671 coumarin Nutrition 0.000 description 2
• 229960000956 coumarin Drugs 0.000 description 2
• 235000014113 dietary fatty acids Nutrition 0.000 description 2
• 238000010790 dilution Methods 0.000 description 2
• 239000012895 dilution Substances 0.000 description 2
• 231100000673 dose–response relationship Toxicity 0.000 description 2
• 238000012377 drug delivery Methods 0.000 description 2
• 239000003995 emulsifying agent Substances 0.000 description 2
• 230000002124 endocrine Effects 0.000 description 2
• 210000005168 endometrial cell Anatomy 0.000 description 2
• 230000002708 enhancing effect Effects 0.000 description 2
• 230000001076 estrogenic effect Effects 0.000 description 2
• NPUKDXXFDDZOKR-LLVKDONJSA-N etomidate Chemical compound CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1 NPUKDXXFDDZOKR-LLVKDONJSA-N 0.000 description 2
• 239000000194 fatty acid Substances 0.000 description 2
• 229930195729 fatty acid Natural products 0.000 description 2
• 150000004665 fatty acids Chemical class 0.000 description 2
• 229940126864 fibroblast growth factor Drugs 0.000 description 2
• 239000012467 final product Substances 0.000 description 2
• 238000003818 flash chromatography Methods 0.000 description 2
• GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
• 239000008103 glucose Substances 0.000 description 2
• 125000005456 glyceride group Chemical group 0.000 description 2
• 229940096919 glycogen Drugs 0.000 description 2
• 238000005469 granulation Methods 0.000 description 2
• 230000003179 granulation Effects 0.000 description 2
• 239000003102 growth factor Substances 0.000 description 2
• 230000009036 growth inhibition Effects 0.000 description 2
• 101150090422 gsk-3 gene Proteins 0.000 description 2
• 125000005114 heteroarylalkoxy group Chemical group 0.000 description 2
• 229930195733 hydrocarbon Natural products 0.000 description 2
• 150000002430 hydrocarbons Chemical class 0.000 description 2
• 150000003840 hydrochlorides Chemical class 0.000 description 2
• 125000002768 hydroxyalkyl group Chemical group 0.000 description 2
• 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 2
• 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
• 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 2
• 238000002347 injection Methods 0.000 description 2
• 239000007924 injection Substances 0.000 description 2
• 238000007917 intracranial administration Methods 0.000 description 2
• 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 2
• 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 2
• 239000008101 lactose Substances 0.000 description 2
• 230000003902 lesion Effects 0.000 description 2
• 201000005296 lung carcinoma Diseases 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 210000003593 megakaryocyte Anatomy 0.000 description 2
• 238000006263 metalation reaction Methods 0.000 description 2
• 208000037819 metastatic cancer Diseases 0.000 description 2
• 208000011575 metastatic malignant neoplasm Diseases 0.000 description 2
• 239000002480 mineral oil Substances 0.000 description 2
• 235000010446 mineral oil Nutrition 0.000 description 2
• 230000001613 neoplastic effect Effects 0.000 description 2
• 125000004433 nitrogen atom Chemical group N* 0.000 description 2
• 231100000252 nontoxic Toxicity 0.000 description 2
• 230000003000 nontoxic effect Effects 0.000 description 2
• 239000000346 nonvolatile oil Substances 0.000 description 2
• 210000000056 organ Anatomy 0.000 description 2
• 201000008482 osteoarthritis Diseases 0.000 description 2
• 230000002611 ovarian Effects 0.000 description 2
• 150000002923 oximes Chemical class 0.000 description 2
• 229940066842 petrolatum Drugs 0.000 description 2
• 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 2
• 239000010452 phosphate Substances 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
• BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
• 229920001282 polysaccharide Polymers 0.000 description 2
• 229910052700 potassium Inorganic materials 0.000 description 2
• 239000002244 precipitate Substances 0.000 description 2
• 238000001556 precipitation Methods 0.000 description 2
• 150000003141 primary amines Chemical class 0.000 description 2
• 230000035755 proliferation Effects 0.000 description 2
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
• 125000006239 protecting group Chemical group 0.000 description 2
• 239000003197 protein kinase B inhibitor Substances 0.000 description 2
• 150000003230 pyrimidines Chemical class 0.000 description 2
• 238000005956 quaternization reaction Methods 0.000 description 2
• 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
• 238000010992 reflux Methods 0.000 description 2
• 230000022983 regulation of cell cycle Effects 0.000 description 2
• 208000037803 restenosis Diseases 0.000 description 2
• 230000037390 scarring Effects 0.000 description 2
• 238000005204 segregation Methods 0.000 description 2
• XIIOFHFUYBLOLW-UHFFFAOYSA-N selpercatinib Chemical compound OC(COC=1C=C(C=2N(C=1)N=CC=2C#N)C=1C=NC(=CC=1)N1CC2N(C(C1)C2)CC=1C=NC(=CC=1)OC)(C)C XIIOFHFUYBLOLW-UHFFFAOYSA-N 0.000 description 2
• 230000035939 shock Effects 0.000 description 2
• 239000000741 silica gel Substances 0.000 description 2
• 229910002027 silica gel Inorganic materials 0.000 description 2
• 238000010898 silica gel chromatography Methods 0.000 description 2
• 235000017557 sodium bicarbonate Nutrition 0.000 description 2
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
• 238000010186 staining Methods 0.000 description 2
• 235000011150 stannous chloride Nutrition 0.000 description 2
• 229960001940 sulfasalazine Drugs 0.000 description 2
• NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 2
• NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 2
• 229940124530 sulfonamide Drugs 0.000 description 2
• 150000003456 sulfonamides Chemical class 0.000 description 2
• 102000013498 tau Proteins Human genes 0.000 description 2
• 108010026424 tau Proteins Proteins 0.000 description 2
• 230000016853 telophase Effects 0.000 description 2
• 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 2
• AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 2
• 206010044325 trachoma Diseases 0.000 description 2
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
• 230000007704 transition Effects 0.000 description 2
• IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 2
• LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
• QKOJLMKWBRBZNQ-UHFFFAOYSA-N (5-fluoro-2-methylphenyl)boronic acid Chemical compound CC1=CC=C(F)C=C1B(O)O QKOJLMKWBRBZNQ-UHFFFAOYSA-N 0.000 description 1
• WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
• KNZUILXTRONLII-UHFFFAOYSA-N 1-[2-(1-methylindol-2-yl)-6-[(5-methyl-1h-pyrazol-3-yl)amino]pyrimidin-4-yl]piperidin-4-ol Chemical compound N1C(C)=CC(NC=2N=C(N=C(C=2)N2CCC(O)CC2)C=2N(C3=CC=CC=C3C=2)C)=N1 KNZUILXTRONLII-UHFFFAOYSA-N 0.000 description 1
• XPYVCRWZAQLYNK-UHFFFAOYSA-N 1-[4-[2-(1-methylindol-2-yl)-6-[(5-methyl-1h-pyrazol-3-yl)amino]pyrimidin-4-yl]piperazin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCN1C1=CC(NC2=NNC(C)=C2)=NC(C=2N(C3=CC=CC=C3C=2)C)=N1 XPYVCRWZAQLYNK-UHFFFAOYSA-N 0.000 description 1
• FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical class C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 1
• RKWWASUTWAFKHA-UHFFFAOYSA-N 1-bromo-2,3-difluorobenzene Chemical compound FC1=CC=CC(Br)=C1F RKWWASUTWAFKHA-UHFFFAOYSA-N 0.000 description 1
• CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical compound CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 description 1
• KDKGWGUUUVROTO-UHFFFAOYSA-N 1-hydroxypiperazine Chemical compound ON1CCNCC1 KDKGWGUUUVROTO-UHFFFAOYSA-N 0.000 description 1
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
• PKDPUENCROCRCH-UHFFFAOYSA-N 1-piperazin-1-ylethanone Chemical compound CC(=O)N1CCNCC1 PKDPUENCROCRCH-UHFFFAOYSA-N 0.000 description 1
• 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
• ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 1
• CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
• BTTNYQZNBZNDOR-UHFFFAOYSA-N 2,4-dichloropyrimidine Chemical compound ClC1=CC=NC(Cl)=N1 BTTNYQZNBZNDOR-UHFFFAOYSA-N 0.000 description 1
• IDRWJSYZUYYGOT-UHFFFAOYSA-N 2,6-dichloro-N-(5-methyl-1H-pyrazol-3-yl)pyrimidin-4-amine 2,4,6-trichloropyrimidine Chemical compound ClC1=NC(=CC(=N1)Cl)Cl.ClC1=NC(=CC(=N1)NC1=NNC(=C1)C)Cl IDRWJSYZUYYGOT-UHFFFAOYSA-N 0.000 description 1
• OCQFNBKMIMGJCZ-UHFFFAOYSA-N 2-(1-benzofuran-2-yl)-6-(4-methylpiperazin-1-yl)-n-(5-methyl-1h-pyrazol-3-yl)pyrimidin-4-amine Chemical compound C1CN(C)CCN1C1=CC(NC2=NNC(C)=C2)=NC(C=2OC3=CC=CC=C3C=2)=N1 OCQFNBKMIMGJCZ-UHFFFAOYSA-N 0.000 description 1
• OQHOJUNACOGFJO-UHFFFAOYSA-N 2-(1-benzofuran-2-yl)-6-n-(5-methyl-1h-pyrazol-3-yl)-4-n-(oxan-4-yl)pyrimidine-4,6-diamine Chemical compound N1C(C)=CC(NC=2N=C(N=C(NC3CCOCC3)C=2)C=2OC3=CC=CC=C3C=2)=N1 OQHOJUNACOGFJO-UHFFFAOYSA-N 0.000 description 1
• RNWZTTJPSDQQKD-UHFFFAOYSA-N 2-(1-methylindol-2-yl)-1h-pyrimidine-4,6-dione Chemical compound C=1C2=CC=CC=C2N(C)C=1C1=NC(=O)CC(=O)N1 RNWZTTJPSDQQKD-UHFFFAOYSA-N 0.000 description 1
• QPNYVIHBNQLGIO-UHFFFAOYSA-N 2-(1-methylindol-2-yl)-6-(4-methylpiperazin-1-yl)-n-(5-methyl-1h-pyrazol-3-yl)pyrimidin-4-amine Chemical compound C1CN(C)CCN1C1=CC(NC2=NNC(C)=C2)=NC(C=2N(C3=CC=CC=C3C=2)C)=N1 QPNYVIHBNQLGIO-UHFFFAOYSA-N 0.000 description 1
• AOIFQKDHKFEQTH-UHFFFAOYSA-N 2-(2,3-dihydro-1,4-benzodioxin-5-yl)-6-(4-methylpiperazin-1-yl)-n-(5-methyl-1h-pyrazol-3-yl)pyrimidin-4-amine Chemical compound C1CN(C)CCN1C1=CC(NC2=NNC(C)=C2)=NC(C=2C=3OCCOC=3C=CC=2)=N1 AOIFQKDHKFEQTH-UHFFFAOYSA-N 0.000 description 1
• XLSOYJGIHPJTRJ-UHFFFAOYSA-N 2-(2,3-dihydro-1,4-benzodioxin-6-yl)-6-(4-methylpiperazin-1-yl)-n-(5-methyl-1h-pyrazol-3-yl)pyrimidin-4-amine Chemical compound C1CN(C)CCN1C1=CC(NC2=NNC(C)=C2)=NC(C=2C=C3OCCOC3=CC=2)=N1 XLSOYJGIHPJTRJ-UHFFFAOYSA-N 0.000 description 1
• DXJZHGPSWQYEEV-UHFFFAOYSA-N 2-(2,3-dimethylphenyl)-4-n-(2-methoxyethyl)-4-n-methyl-6-n-(5-methyl-1h-pyrazol-3-yl)pyrimidine-4,6-diamine Chemical compound N=1C(C=2C(=C(C)C=CC=2)C)=NC(N(C)CCOC)=CC=1NC=1C=C(C)NN=1 DXJZHGPSWQYEEV-UHFFFAOYSA-N 0.000 description 1
• IEYGSECSPKRDMZ-UHFFFAOYSA-N 2-(2,3-dimethylphenyl)-6-n-(5-methyl-1h-pyrazol-3-yl)-4-n-(oxan-4-yl)pyrimidine-4,6-diamine Chemical compound N1C(C)=CC(NC=2N=C(N=C(NC3CCOCC3)C=2)C=2C(=C(C)C=CC=2)C)=N1 IEYGSECSPKRDMZ-UHFFFAOYSA-N 0.000 description 1
• VWNIBHQHVGWSCZ-UHFFFAOYSA-N 2-(2,4-difluorophenyl)-6-(4-methylpiperazin-1-yl)-n-(5-methyl-1h-pyrazol-3-yl)pyrimidin-4-amine Chemical compound C1CN(C)CCN1C1=CC(NC2=NNC(C)=C2)=NC(C=2C(=CC(F)=CC=2)F)=N1 VWNIBHQHVGWSCZ-UHFFFAOYSA-N 0.000 description 1
• VDHUTFZEDWJFIP-UHFFFAOYSA-N 2-(2,5-difluorophenyl)-4-n-(2-methoxyethyl)-4-n-methyl-6-n-(5-methyl-1h-pyrazol-3-yl)pyrimidine-4,6-diamine Chemical compound N=1C(C=2C(=CC=C(F)C=2)F)=NC(N(C)CCOC)=CC=1NC=1C=C(C)NN=1 VDHUTFZEDWJFIP-UHFFFAOYSA-N 0.000 description 1
• AUIKAHLJRJUSEC-UHFFFAOYSA-N 2-(2,5-difluorophenyl)-4-n-[2-(dimethylamino)ethyl]-4-n-methyl-6-n-(5-methyl-1h-pyrazol-3-yl)pyrimidine-4,6-diamine Chemical compound N=1C(C=2C(=CC=C(F)C=2)F)=NC(N(C)CCN(C)C)=CC=1NC=1C=C(C)NN=1 AUIKAHLJRJUSEC-UHFFFAOYSA-N 0.000 description 1
• LMZMYHWZTCKWPJ-UHFFFAOYSA-N 2-(2,5-dimethylphenyl)-4-n-(2-methoxyethyl)-4-n-methyl-6-n-(5-methyl-1h-pyrazol-3-yl)pyrimidine-4,6-diamine Chemical compound N=1C(C=2C(=CC=C(C)C=2)C)=NC(N(C)CCOC)=CC=1NC=1C=C(C)NN=1 LMZMYHWZTCKWPJ-UHFFFAOYSA-N 0.000 description 1
• IKWDTVLMKFLCHF-UHFFFAOYSA-N 2-(2,6-dimethylphenyl)-4-n-(2-methoxyethyl)-4-n-methyl-6-n-(5-methyl-1h-pyrazol-3-yl)pyrimidine-4,6-diamine Chemical compound N=1C(C=2C(=CC=CC=2C)C)=NC(N(C)CCOC)=CC=1NC=1C=C(C)NN=1 IKWDTVLMKFLCHF-UHFFFAOYSA-N 0.000 description 1
• LAVXNYZWDSQIRF-UHFFFAOYSA-N 2-(2-chlorophenyl)-6-n-(5-methyl-1h-pyrazol-3-yl)-4-n-(oxan-4-yl)pyrimidine-4,6-diamine Chemical compound N1C(C)=CC(NC=2N=C(N=C(NC3CCOCC3)C=2)C=2C(=CC=CC=2)Cl)=N1 LAVXNYZWDSQIRF-UHFFFAOYSA-N 0.000 description 1
• SPKIITVIBZCLBL-UHFFFAOYSA-N 2-(2-ethylphenyl)-6-n-(5-methyl-1h-pyrazol-3-yl)-4-n-(oxan-4-yl)pyrimidine-4,6-diamine Chemical compound CCC1=CC=CC=C1C1=NC(NC2CCOCC2)=CC(NC2=NNC(C)=C2)=N1 SPKIITVIBZCLBL-UHFFFAOYSA-N 0.000 description 1
• NYWXOAAAWHKXMH-UHFFFAOYSA-N 2-(2-fluorophenyl)-6-(4-methylpiperazin-1-yl)-n-(5-methyl-1h-pyrazol-3-yl)pyrimidin-4-amine Chemical compound C1CN(C)CCN1C1=CC(NC2=NNC(C)=C2)=NC(C=2C(=CC=CC=2)F)=N1 NYWXOAAAWHKXMH-UHFFFAOYSA-N 0.000 description 1
• NMEWSRKISDOLRF-UHFFFAOYSA-N 2-(2-methoxyphenyl)-6-(4-methylpiperazin-1-yl)-n-(5-methyl-1h-pyrazol-3-yl)pyrimidin-4-amine Chemical compound COC1=CC=CC=C1C1=NC(NC2=NNC(C)=C2)=CC(N2CCN(C)CC2)=N1 NMEWSRKISDOLRF-UHFFFAOYSA-N 0.000 description 1
• FNSMNVPTQAIZMB-UHFFFAOYSA-N 2-(2-methylphenyl)-6-(4-methylpiperazin-1-yl)-n-(5-methyl-1h-pyrazol-3-yl)pyrimidin-4-amine Chemical compound C1CN(C)CCN1C1=CC(NC2=NNC(C)=C2)=NC(C=2C(=CC=CC=2)C)=N1 FNSMNVPTQAIZMB-UHFFFAOYSA-N 0.000 description 1
• SSQMYCUATQBYLN-UHFFFAOYSA-N 2-(3-fluorophenyl)-6-(4-methylpiperazin-1-yl)-n-(5-methyl-1h-pyrazol-3-yl)pyrimidin-4-amine Chemical compound C1CN(C)CCN1C1=CC(NC2=NNC(C)=C2)=NC(C=2C=C(F)C=CC=2)=N1 SSQMYCUATQBYLN-UHFFFAOYSA-N 0.000 description 1
• ZMRRQLYNPXHNOL-UHFFFAOYSA-N 2-(3-fluorophenyl)-6-n-(5-methyl-1h-pyrazol-3-yl)-4-n-(oxan-4-yl)pyrimidine-4,6-diamine Chemical compound N1C(C)=CC(NC=2N=C(N=C(NC3CCOCC3)C=2)C=2C=C(F)C=CC=2)=N1 ZMRRQLYNPXHNOL-UHFFFAOYSA-N 0.000 description 1
• JYPPKEAUZIXHBK-UHFFFAOYSA-N 2-(3-methoxyphenyl)-6-(4-methylpiperazin-1-yl)-n-(5-methyl-1h-pyrazol-3-yl)pyrimidin-4-amine Chemical compound COC1=CC=CC(C=2N=C(C=C(NC3=NNC(C)=C3)N=2)N2CCN(C)CC2)=C1 JYPPKEAUZIXHBK-UHFFFAOYSA-N 0.000 description 1
• VXBAORVAJISYTA-UHFFFAOYSA-N 2-(4-fluorophenyl)-6-(4-methylpiperazin-1-yl)-n-(5-methyl-1h-pyrazol-3-yl)pyrimidin-4-amine Chemical compound C1CN(C)CCN1C1=CC(NC2=NNC(C)=C2)=NC(C=2C=CC(F)=CC=2)=N1 VXBAORVAJISYTA-UHFFFAOYSA-N 0.000 description 1
• SAAPLVBMWOXALR-UHFFFAOYSA-N 2-(4-fluorophenyl)-6-n-(5-methyl-1h-pyrazol-3-yl)-4-n-(oxan-4-yl)pyrimidine-4,6-diamine Chemical compound N1C(C)=CC(NC=2N=C(N=C(NC3CCOCC3)C=2)C=2C=CC(F)=CC=2)=N1 SAAPLVBMWOXALR-UHFFFAOYSA-N 0.000 description 1
• DCEQUYDETJQUDS-UHFFFAOYSA-N 2-(4-methoxyphenyl)-6-n-(5-methyl-1h-pyrazol-3-yl)-4-n-(oxan-4-yl)pyrimidine-4,6-diamine Chemical compound C1=CC(OC)=CC=C1C1=NC(NC2CCOCC2)=CC(NC2=NNC(C)=C2)=N1 DCEQUYDETJQUDS-UHFFFAOYSA-N 0.000 description 1
• MFMPCVIYZYPAII-UHFFFAOYSA-N 2-(4-methylphenyl)-6-(4-methylpiperazin-1-yl)-n-(5-methyl-1h-pyrazol-3-yl)pyrimidin-4-amine Chemical compound C1CN(C)CCN1C1=CC(NC2=NNC(C)=C2)=NC(C=2C=CC(C)=CC=2)=N1 MFMPCVIYZYPAII-UHFFFAOYSA-N 0.000 description 1
• PVULOZNLCMHDGN-UHFFFAOYSA-N 2-(4-tert-butylphenyl)-6-(4-methylpiperazin-1-yl)-n-(5-methyl-1h-pyrazol-3-yl)pyrimidin-4-amine Chemical compound C1CN(C)CCN1C1=CC(NC2=NNC(C)=C2)=NC(C=2C=CC(=CC=2)C(C)(C)C)=N1 PVULOZNLCMHDGN-UHFFFAOYSA-N 0.000 description 1
• QNESVAVPPPBLNC-UHFFFAOYSA-N 2-(furan-2-yl)-6-(4-methylpiperazin-1-yl)-n-(5-methyl-1h-pyrazol-3-yl)pyrimidin-4-amine Chemical compound C1CN(C)CCN1C1=CC(NC2=NNC(C)=C2)=NC(C=2OC=CC=2)=N1 QNESVAVPPPBLNC-UHFFFAOYSA-N 0.000 description 1
• RMSMMPWATWVBBT-UHFFFAOYSA-N 2-(furan-2-yl)-n-(5-methyl-1h-pyrazol-3-yl)pyrimidin-4-amine Chemical compound N1C(C)=CC(NC=2N=C(N=CC=2)C=2OC=CC=2)=N1 RMSMMPWATWVBBT-UHFFFAOYSA-N 0.000 description 1
• REVBFEUPNPNFQI-UHFFFAOYSA-N 2-[3-(dimethylamino)phenyl]-4-n-(2-methoxyethyl)-4-n-methyl-6-n-(5-methyl-1h-pyrazol-3-yl)pyrimidine-4,6-diamine Chemical compound N=1C(C=2C=C(C=CC=2)N(C)C)=NC(N(C)CCOC)=CC=1NC=1C=C(C)NN=1 REVBFEUPNPNFQI-UHFFFAOYSA-N 0.000 description 1
• NOYPWDDUJKDZBB-UHFFFAOYSA-N 2-[3-(dimethylamino)phenyl]-6-(4-methylpiperazin-1-yl)-n-(5-methyl-1h-pyrazol-3-yl)pyrimidin-4-amine Chemical compound CN(C)C1=CC=CC(C=2N=C(C=C(NC3=NNC(C)=C3)N=2)N2CCN(C)CC2)=C1 NOYPWDDUJKDZBB-UHFFFAOYSA-N 0.000 description 1
• WSBKQOFMPKHHDB-UHFFFAOYSA-N 2-[4-(trifluoromethyl)phenyl]pyrimidin-4-amine Chemical compound NC1=CC=NC(C=2C=CC(=CC=2)C(F)(F)F)=N1 WSBKQOFMPKHHDB-UHFFFAOYSA-N 0.000 description 1
• KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 1
• GHEGRRNRBHCGFV-UHFFFAOYSA-N 2-chloro-6-(4-methylpiperazin-1-yl)-n-(5-methyl-1h-pyrazol-3-yl)pyrimidin-4-amine Chemical compound C1CN(C)CCN1C1=CC(NC2=NNC(C)=C2)=NC(Cl)=N1 GHEGRRNRBHCGFV-UHFFFAOYSA-N 0.000 description 1
• 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
• 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
• LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
• 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 1
• 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
• 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
• LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
• ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
• 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
• XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
• 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
• 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
• 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
• VZPHBCSNAAUQDS-UHFFFAOYSA-N 4,6-dichloro-2-(furan-2-yl)pyrimidine Chemical compound ClC1=CC(Cl)=NC(C=2OC=CC=2)=N1 VZPHBCSNAAUQDS-UHFFFAOYSA-N 0.000 description 1
• YTAIZNZIWJIGOB-UHFFFAOYSA-N 4-[4-(4-methylpiperazin-1-yl)-6-[(5-methyl-1h-pyrazol-3-yl)amino]pyrimidin-2-yl]benzonitrile Chemical compound C1CN(C)CCN1C1=CC(NC2=NNC(C)=C2)=NC(C=2C=CC(=CC=2)C#N)=N1 YTAIZNZIWJIGOB-UHFFFAOYSA-N 0.000 description 1
• PQQCEIMCLFXJLN-UHFFFAOYSA-N 4-butylphosphanyl-n,n-dimethylaniline Chemical compound CCCCPC1=CC=C(N(C)C)C=C1 PQQCEIMCLFXJLN-UHFFFAOYSA-N 0.000 description 1
• 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1
• URDVKOFSZIYHFY-UHFFFAOYSA-N 4-n-(5-methyl-1h-pyrazol-3-yl)-6-n-(2-morpholin-4-ylethyl)-2-phenylpyrimidine-4,6-diamine Chemical compound N1C(C)=CC(NC=2N=C(N=C(NCCN3CCOCC3)C=2)C=2C=CC=CC=2)=N1 URDVKOFSZIYHFY-UHFFFAOYSA-N 0.000 description 1
• UYWNOWRRSZEDDE-UHFFFAOYSA-N 4-n-[2-(dimethylamino)ethyl]-2-(2,3-dimethylphenyl)-4-n-methyl-6-n-(5-methyl-1h-pyrazol-3-yl)pyrimidine-4,6-diamine Chemical compound N=1C(C=2C(=C(C)C=CC=2)C)=NC(N(C)CCN(C)C)=CC=1NC=1C=C(C)NN=1 UYWNOWRRSZEDDE-UHFFFAOYSA-N 0.000 description 1
• OHADPTWGLOASOI-UHFFFAOYSA-N 4-n-[2-(dimethylamino)ethyl]-4-n-methyl-2-(3-methylphenyl)-6-n-(5-methyl-1h-pyrazol-3-yl)pyrimidine-4,6-diamine Chemical compound N=1C(C=2C=C(C)C=CC=2)=NC(N(C)CCN(C)C)=CC=1NC=1C=C(C)NN=1 OHADPTWGLOASOI-UHFFFAOYSA-N 0.000 description 1
• YRCXBAWIHUZQDI-UHFFFAOYSA-N 4-n-[2-(dimethylamino)ethyl]-4-n-methyl-6-n-(5-methyl-1h-pyrazol-3-yl)-2-phenylpyrimidine-4,6-diamine Chemical compound N=1C(C=2C=CC=CC=2)=NC(N(C)CCN(C)C)=CC=1NC=1C=C(C)NN=1 YRCXBAWIHUZQDI-UHFFFAOYSA-N 0.000 description 1
• 125000004487 4-tetrahydropyranyl group Chemical group [H]C1([H])OC([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
• ZNNRVSOVVLYQBV-UHFFFAOYSA-N 5-nitro-1h-pyrimidin-2-one Chemical compound [O-][N+](=O)C=1C=NC(=O)NC=1 ZNNRVSOVVLYQBV-UHFFFAOYSA-N 0.000 description 1
• CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 1
• QFFVPNCJGRYGJK-UHFFFAOYSA-N 6-(4-methylpiperazin-1-yl)-n-(5-methyl-1h-pyrazol-3-yl)-2-(3-phenylmethoxyphenyl)pyrimidin-4-amine Chemical compound C1CN(C)CCN1C1=CC(NC2=NNC(C)=C2)=NC(C=2C=C(OCC=3C=CC=CC=3)C=CC=2)=N1 QFFVPNCJGRYGJK-UHFFFAOYSA-N 0.000 description 1
• ULELGXPWXISMPH-UHFFFAOYSA-N 6-chloro-2-(furan-2-yl)-N-(5-methyl-1H-pyrazol-3-yl)pyrimidin-4-amine 4,6-dichloro-2-(furan-2-yl)pyrimidine Chemical compound ClC1=NC(=NC(=C1)Cl)C=1OC=CC1.ClC1=CC(=NC(=N1)C=1OC=CC1)NC1=NNC(=C1)C ULELGXPWXISMPH-UHFFFAOYSA-N 0.000 description 1
• GXABZCDVZOPBPI-UHFFFAOYSA-N 6-n-(2-methoxyethyl)-4-n-(5-methyl-1h-pyrazol-3-yl)-2-phenylpyrimidine-4,6-diamine Chemical compound N=1C(C=2C=CC=CC=2)=NC(NCCOC)=CC=1NC=1C=C(C)NN=1 GXABZCDVZOPBPI-UHFFFAOYSA-N 0.000 description 1
• BAZZZVCGCBLZNT-UHFFFAOYSA-N 6-n-[2-(4-methylpiperazin-1-yl)ethyl]-4-n-(5-methyl-1h-pyrazol-3-yl)-2-phenylpyrimidine-4,6-diamine Chemical compound C1CN(C)CCN1CCNC1=CC(NC2=NNC(C)=C2)=NC(C=2C=CC=CC=2)=N1 BAZZZVCGCBLZNT-UHFFFAOYSA-N 0.000 description 1
• FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
• QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
• 239000005541 ACE inhibitor Substances 0.000 description 1
• ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 1
• 206010000050 Abdominal adhesions Diseases 0.000 description 1
• IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
• 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
• 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
• QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
• 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 description 1
• 208000003120 Angiofibroma Diseases 0.000 description 1
• 201000003076 Angiosarcoma Diseases 0.000 description 1
• 102100032306 Aurora kinase B Human genes 0.000 description 1
• 102100026630 Aurora kinase C Human genes 0.000 description 1
• 108090000805 Aurora kinase C Proteins 0.000 description 1
• 229940123877 Aurora kinase inhibitor Drugs 0.000 description 1
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
• 208000035143 Bacterial infection Diseases 0.000 description 1
• 206010044583 Bartonella Infections Diseases 0.000 description 1
• 208000009137 Behcet syndrome Diseases 0.000 description 1
• 239000005711 Benzoic acid Substances 0.000 description 1
• 102000015735 Beta-catenin Human genes 0.000 description 1
• 108060000903 Beta-catenin Proteins 0.000 description 1
• 229940123208 Biguanide Drugs 0.000 description 1
• 108010017384 Blood Proteins Proteins 0.000 description 1
• 102000004506 Blood Proteins Human genes 0.000 description 1
• 208000019838 Blood disease Diseases 0.000 description 1
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
• 201000006474 Brain Ischemia Diseases 0.000 description 1
• 208000011691 Burkitt lymphomas Diseases 0.000 description 1
• FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
• FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
• RCQNNAGURSYVGE-UHFFFAOYSA-N C(C)N(C(C)C)CC.O1C(=CC2=C1C=CC=C2)C2=NC(=CC(=N2)Cl)Cl Chemical compound C(C)N(C(C)C)CC.O1C(=CC2=C1C=CC=C2)C2=NC(=CC(=N2)Cl)Cl RCQNNAGURSYVGE-UHFFFAOYSA-N 0.000 description 1
• 229940127291 Calcium channel antagonist Drugs 0.000 description 1
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
• 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
• 208000006029 Cardiomegaly Diseases 0.000 description 1
• 208000003732 Cat-scratch disease Diseases 0.000 description 1
• 206010008120 Cerebral ischaemia Diseases 0.000 description 1
• 206010008342 Cervix carcinoma Diseases 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
• 229920001268 Cholestyramine Polymers 0.000 description 1
• 208000036086 Chromosome Duplication Diseases 0.000 description 1
• 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
• 208000032544 Cicatrix Diseases 0.000 description 1
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
• 206010009900 Colitis ulcerative Diseases 0.000 description 1
• 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
• 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
• 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
• 208000011231 Crohn disease Diseases 0.000 description 1
• 229920000858 Cyclodextrin Polymers 0.000 description 1
• PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
• 229930105110 Cyclosporin A Natural products 0.000 description 1
• 108010036949 Cyclosporine Proteins 0.000 description 1
• 201000003883 Cystic fibrosis Diseases 0.000 description 1
• 102000004127 Cytokines Human genes 0.000 description 1
• 108090000695 Cytokines Proteins 0.000 description 1
• 241000701022 Cytomegalovirus Species 0.000 description 1
• 201000004624 Dermatitis Diseases 0.000 description 1
• YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
• 208000007033 Dysgerminoma Diseases 0.000 description 1
• 102100030013 Endoribonuclease Human genes 0.000 description 1
• 101710199605 Endoribonuclease Proteins 0.000 description 1
• 241000792859 Enema Species 0.000 description 1
• NRFQZTCQAYEXEE-UHFFFAOYSA-N Fenclorim Chemical compound ClC1=CC(Cl)=NC(C=2C=CC=CC=2)=N1 NRFQZTCQAYEXEE-UHFFFAOYSA-N 0.000 description 1
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
• BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
• 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 1
• 206010018364 Glomerulonephritis Diseases 0.000 description 1
• 239000004471 Glycine Substances 0.000 description 1
• AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
• 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
• 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
• 241000590002 Helicobacter pylori Species 0.000 description 1
• 208000001258 Hemangiosarcoma Diseases 0.000 description 1
• 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
• 208000032843 Hemorrhage Diseases 0.000 description 1
• 206010019842 Hepatomegaly Diseases 0.000 description 1
• 101710103773 Histone H2B Proteins 0.000 description 1
• 102100021639 Histone H2B type 1-K Human genes 0.000 description 1
• 101000988651 Homo sapiens Humanin-like 1 Proteins 0.000 description 1
• 101001081172 Homo sapiens Humanin-like 11 Proteins 0.000 description 1
• 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 1
• 108091006905 Human Serum Albumin Proteins 0.000 description 1
• 102000008100 Human Serum Albumin Human genes 0.000 description 1
• 102100027736 Humanin-like 11 Human genes 0.000 description 1
• CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
• AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
• 208000037147 Hypercalcaemia Diseases 0.000 description 1
• XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 208000029462 Immunodeficiency disease Diseases 0.000 description 1
• 102000004877 Insulin Human genes 0.000 description 1
• 108090001061 Insulin Proteins 0.000 description 1
• 229940122355 Insulin sensitizer Drugs 0.000 description 1
• 108090000862 Ion Channels Proteins 0.000 description 1
• 102000004310 Ion Channels Human genes 0.000 description 1
• 208000002260 Keloid Diseases 0.000 description 1
• 102000019293 Kinesin-like proteins Human genes 0.000 description 1
• 108050006659 Kinesin-like proteins Proteins 0.000 description 1
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
• 229930182816 L-glutamine Natural products 0.000 description 1
• 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 1
• JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
• 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 description 1
• WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
• OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
• 241000124008 Mammalia Species 0.000 description 1
• 206010027304 Menopausal symptoms Diseases 0.000 description 1
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
• 102000029749 Microtubule Human genes 0.000 description 1
• 108091022875 Microtubule Proteins 0.000 description 1
• 208000034578 Multiple myelomas Diseases 0.000 description 1
• 206010062207 Mycobacterial infection Diseases 0.000 description 1
• 102000047918 Myelin Basic Human genes 0.000 description 1
• 101710107068 Myelin basic protein Proteins 0.000 description 1
• 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
• 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
• WVMXNDFLTZOTNM-UHFFFAOYSA-N NC1CCOCC1.N1=CN=C(C=C1N)N Chemical compound NC1CCOCC1.N1=CN=C(C=C1N)N WVMXNDFLTZOTNM-UHFFFAOYSA-N 0.000 description 1
• 229910002651 NO3 Inorganic materials 0.000 description 1
• 239000007832 Na2SO4 Substances 0.000 description 1
• 108010025020 Nerve Growth Factor Proteins 0.000 description 1
• 102000007072 Nerve Growth Factors Human genes 0.000 description 1
• PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
• NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
• GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
• QHFZTSSWYWIZLX-UHFFFAOYSA-N O1C=CC=C1.ClC1=NC(=NC(=C1)Cl)C=1OC=CC1 Chemical compound O1C=CC=C1.ClC1=NC(=NC(=C1)Cl)C=1OC=CC1 QHFZTSSWYWIZLX-UHFFFAOYSA-N 0.000 description 1
• 208000022873 Ocular disease Diseases 0.000 description 1
• 239000005642 Oleic acid Substances 0.000 description 1
• ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
• 206010061535 Ovarian neoplasm Diseases 0.000 description 1
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
• 108010001441 Phosphopeptides Proteins 0.000 description 1
• 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
• 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
• 238000003482 Pinner synthesis reaction Methods 0.000 description 1
• 206010035226 Plasma cell myeloma Diseases 0.000 description 1
• 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
• 208000020584 Polyploidy Diseases 0.000 description 1
• 229920001214 Polysorbate 60 Polymers 0.000 description 1
• 239000004793 Polystyrene Substances 0.000 description 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
• 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 description 1
• XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
• 108010007568 Protamines Proteins 0.000 description 1
• 102000007327 Protamines Human genes 0.000 description 1
• 206010038934 Retinopathy proliferative Diseases 0.000 description 1
• FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 description 1
• 206010039710 Scleroderma Diseases 0.000 description 1
• 208000034189 Sclerosis Diseases 0.000 description 1
• 101710113029 Serine/threonine-protein kinase Proteins 0.000 description 1
• 229910004298 SiO 2 Inorganic materials 0.000 description 1
• PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
• HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
• 208000005718 Stomach Neoplasms Diseases 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
• 229940100389 Sulfonylurea Drugs 0.000 description 1
• 210000001744 T-lymphocyte Anatomy 0.000 description 1
• QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
• 229940123237 Taxane Drugs 0.000 description 1
• ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
• 102000040945 Transcription factor Human genes 0.000 description 1
• 108091023040 Transcription factor Proteins 0.000 description 1
• 239000007983 Tris buffer Substances 0.000 description 1
• YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
• 102100040247 Tumor necrosis factor Human genes 0.000 description 1
• 201000006704 Ulcerative Colitis Diseases 0.000 description 1
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
• 206010064513 Vaginal septum Diseases 0.000 description 1
• 206010052428 Wound Diseases 0.000 description 1
• 208000027418 Wounds and injury Diseases 0.000 description 1
• 230000001594 aberrant effect Effects 0.000 description 1
• 229940124532 absorption promoter Drugs 0.000 description 1
• 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
• PWQLZSHJRGGLBC-UHFFFAOYSA-N acetonitrile;carbon dioxide Chemical compound CC#N.O=C=O PWQLZSHJRGGLBC-UHFFFAOYSA-N 0.000 description 1
• AUYMQLBAJYSOJY-UHFFFAOYSA-N acetyl acetate 1-methylindole-2-carbonitrile Chemical compound C(C)(=O)OC(C)=O.CN1C(=CC2=CC=CC=C12)C#N AUYMQLBAJYSOJY-UHFFFAOYSA-N 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
• 125000004423 acyloxy group Chemical group 0.000 description 1
• 208000002517 adenoid cystic carcinoma Diseases 0.000 description 1
• WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
• 229940009456 adriamycin Drugs 0.000 description 1
• 206010064930 age-related macular degeneration Diseases 0.000 description 1
• 229940072056 alginate Drugs 0.000 description 1
• 235000010443 alginic acid Nutrition 0.000 description 1
• 229920000615 alginic acid Polymers 0.000 description 1
• 229910052783 alkali metal Inorganic materials 0.000 description 1
• 150000001340 alkali metals Chemical class 0.000 description 1
• 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
• 150000001342 alkaline earth metals Chemical class 0.000 description 1
• 125000000033 alkoxyamino group Chemical group 0.000 description 1
• 125000000278 alkyl amino alkyl group Chemical group 0.000 description 1
• 230000000172 allergic effect Effects 0.000 description 1
• 231100000360 alopecia Toxicity 0.000 description 1
• 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
• AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
• CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
• 229940063655 aluminum stearate Drugs 0.000 description 1
• 238000005576 amination reaction Methods 0.000 description 1
• 125000004103 aminoalkyl group Chemical group 0.000 description 1
• 235000019270 ammonium chloride Nutrition 0.000 description 1
• 208000007502 anemia Diseases 0.000 description 1
• 208000036878 aneuploidy Diseases 0.000 description 1
• 231100001075 aneuploidy Toxicity 0.000 description 1
• 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
• 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
• 230000001773 anti-convulsant effect Effects 0.000 description 1
• 229940121363 anti-inflammatory agent Drugs 0.000 description 1
• 239000002260 anti-inflammatory agent Substances 0.000 description 1
• 230000001062 anti-nausea Effects 0.000 description 1
• 230000001028 anti-proliverative effect Effects 0.000 description 1
• 229940125681 anticonvulsant agent Drugs 0.000 description 1
• 239000001961 anticonvulsive agent Substances 0.000 description 1
• 229940082992 antihypertensives mao inhibitors Drugs 0.000 description 1
• 239000000063 antileukemic agent Substances 0.000 description 1
• 239000002246 antineoplastic agent Substances 0.000 description 1
• 239000000939 antiparkinson agent Substances 0.000 description 1
• 239000003443 antiviral agent Substances 0.000 description 1
• 230000006907 apoptotic process Effects 0.000 description 1
• 238000013459 approach Methods 0.000 description 1
• 239000000010 aprotic solvent Substances 0.000 description 1
• 229910052786 argon Inorganic materials 0.000 description 1
• 238000000149 argon plasma sintering Methods 0.000 description 1
• 206010003246 arthritis Diseases 0.000 description 1
• 150000001499 aryl bromides Chemical class 0.000 description 1
• 229940009098 aspartate Drugs 0.000 description 1
• 208000010668 atopic eczema Diseases 0.000 description 1
• 239000003719 aurora kinase inhibitor Substances 0.000 description 1
• 208000022362 bacterial infectious disease Diseases 0.000 description 1
• 206010004145 bartonellosis Diseases 0.000 description 1
• 235000013871 bee wax Nutrition 0.000 description 1
• 239000012166 beeswax Substances 0.000 description 1
• 125000005501 benzalkonium group Chemical class 0.000 description 1
• 125000000043 benzamido group Chemical group [H]N([*])C(=O)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
• 229940077388 benzenesulfonate Drugs 0.000 description 1
• SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
• 229940050390 benzoate Drugs 0.000 description 1
• 235000010233 benzoic acid Nutrition 0.000 description 1
• 125000005872 benzooxazolyl group Chemical group 0.000 description 1
• 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
• 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
• 239000002876 beta blocker Substances 0.000 description 1
• 229940097320 beta blocking agent Drugs 0.000 description 1
• 150000004283 biguanides Chemical class 0.000 description 1
• 230000000740 bleeding effect Effects 0.000 description 1
• 230000023555 blood coagulation Effects 0.000 description 1
• 210000001124 body fluid Anatomy 0.000 description 1
• 239000010839 body fluid Substances 0.000 description 1
• ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
• 201000008275 breast carcinoma Diseases 0.000 description 1
• 210000004899 c-terminal region Anatomy 0.000 description 1
• 239000000480 calcium channel blocker Substances 0.000 description 1
• MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
• 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
• 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
• 235000011089 carbon dioxide Nutrition 0.000 description 1
• 229910002091 carbon monoxide Inorganic materials 0.000 description 1
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
• 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
• 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
• 239000012876 carrier material Substances 0.000 description 1
• 239000004359 castor oil Substances 0.000 description 1
• 235000019438 castor oil Nutrition 0.000 description 1
• 230000003197 catalytic effect Effects 0.000 description 1
• 238000004113 cell culture Methods 0.000 description 1
• 230000022131 cell cycle Effects 0.000 description 1
• 230000006369 cell cycle progression Effects 0.000 description 1
• 230000030833 cell death Effects 0.000 description 1
• 230000032823 cell division Effects 0.000 description 1
• 230000001413 cellular effect Effects 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 210000002230 centromere Anatomy 0.000 description 1
• 210000003793 centrosome Anatomy 0.000 description 1
• 206010008118 cerebral infarction Diseases 0.000 description 1
• 201000010881 cervical cancer Diseases 0.000 description 1
• 229940081733 cetearyl alcohol Drugs 0.000 description 1
• 239000003610 charcoal Substances 0.000 description 1
• 239000003638 chemical reducing agent Substances 0.000 description 1
• 238000002512 chemotherapy Methods 0.000 description 1
• 125000001309 chloro group Chemical group Cl* 0.000 description 1
• 239000000544 cholinesterase inhibitor Substances 0.000 description 1
• 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
• 229960001265 ciclosporin Drugs 0.000 description 1
• 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
• 238000000975 co-precipitation Methods 0.000 description 1
• 229940110456 cocoa butter Drugs 0.000 description 1
• 235000019868 cocoa butter Nutrition 0.000 description 1
• 239000008119 colloidal silica Substances 0.000 description 1
• 229940047120 colony stimulating factors Drugs 0.000 description 1
• 239000003086 colorant Substances 0.000 description 1
• 239000000599 controlled substance Substances 0.000 description 1
• 150000001907 coumarones Chemical class 0.000 description 1
• 239000013078 crystal Substances 0.000 description 1
• 238000002425 crystallisation Methods 0.000 description 1
• 230000008025 crystallization Effects 0.000 description 1
• 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
• 125000000392 cycloalkenyl group Chemical group 0.000 description 1
• 229940097362 cyclodextrins Drugs 0.000 description 1
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 229930182912 cyclosporin Natural products 0.000 description 1
• 230000003436 cytoskeletal effect Effects 0.000 description 1
• 229940127089 cytotoxic agent Drugs 0.000 description 1
• 238000002784 cytotoxicity assay Methods 0.000 description 1
• 231100000263 cytotoxicity test Toxicity 0.000 description 1
• 238000012217 deletion Methods 0.000 description 1
• 230000037430 deletion Effects 0.000 description 1
• 239000003599 detergent Substances 0.000 description 1
• 229910052805 deuterium Inorganic materials 0.000 description 1
• 238000011161 development Methods 0.000 description 1
• 230000018109 developmental process Effects 0.000 description 1
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
• 229960003957 dexamethasone Drugs 0.000 description 1
• 125000004985 dialkyl amino alkyl group Chemical group 0.000 description 1
• 150000004985 diamines Chemical class 0.000 description 1
• 235000005911 diet Nutrition 0.000 description 1
• 230000037213 diet Effects 0.000 description 1
• 230000004069 differentiation Effects 0.000 description 1
• GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
• 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
• BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
• 238000004090 dissolution Methods 0.000 description 1
• VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
• 239000002934 diuretic Substances 0.000 description 1
• 229940030606 diuretics Drugs 0.000 description 1
• MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
• 229940043264 dodecyl sulfate Drugs 0.000 description 1
• 210000003717 douglas' pouch Anatomy 0.000 description 1
• 239000000890 drug combination Substances 0.000 description 1
• 239000013583 drug formulation Substances 0.000 description 1
• 239000003792 electrolyte Substances 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 230000032692 embryo implantation Effects 0.000 description 1
• 238000004945 emulsification Methods 0.000 description 1
• 230000001804 emulsifying effect Effects 0.000 description 1
• 239000008387 emulsifying waxe Substances 0.000 description 1
• 210000004696 endometrium Anatomy 0.000 description 1
• 230000034311 endomitotic cell cycle Effects 0.000 description 1
• 239000002158 endotoxin Substances 0.000 description 1
• 239000007920 enema Substances 0.000 description 1
• 229940095399 enema Drugs 0.000 description 1
• 239000003623 enhancer Substances 0.000 description 1
• 230000007613 environmental effect Effects 0.000 description 1
• 230000002255 enzymatic effect Effects 0.000 description 1
• 238000009164 estrogen replacement therapy Methods 0.000 description 1
• CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
• BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
• 125000006437 ethyl cyclopropyl group Chemical group 0.000 description 1
• 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 1
• 125000006260 ethylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])C([H])([H])[H] 0.000 description 1
• DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
• 210000003527 eukaryotic cell Anatomy 0.000 description 1
• 230000029142 excretion Effects 0.000 description 1
• 230000001747 exhibiting effect Effects 0.000 description 1
• 230000031376 exit from mitosis Effects 0.000 description 1
• 238000001125 extrusion Methods 0.000 description 1
• 235000019197 fats Nutrition 0.000 description 1
• 210000003608 fece Anatomy 0.000 description 1
• 239000012091 fetal bovine serum Substances 0.000 description 1
• RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical group C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 1
• 230000001497 fibrovascular Effects 0.000 description 1
• 229960002949 fluorouracil Drugs 0.000 description 1
• 230000003325 follicular Effects 0.000 description 1
• 239000012458 free base Substances 0.000 description 1
• 108010074605 gamma-Globulins Proteins 0.000 description 1
• 206010017758 gastric cancer Diseases 0.000 description 1
• 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 1
• 230000014509 gene expression Effects 0.000 description 1
• 239000011521 glass Substances 0.000 description 1
• 230000004153 glucose metabolism Effects 0.000 description 1
• ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
• 229960002449 glycine Drugs 0.000 description 1
• 210000003714 granulocyte Anatomy 0.000 description 1
• 238000000227 grinding Methods 0.000 description 1
• 239000001963 growth medium Substances 0.000 description 1
• 125000000262 haloalkenyl group Chemical group 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 238000010438 heat treatment Methods 0.000 description 1
• 229940037467 helicobacter pylori Drugs 0.000 description 1
• 201000002222 hemangioblastoma Diseases 0.000 description 1
• 208000014951 hematologic disease Diseases 0.000 description 1
• 208000018706 hematopoietic system disease Diseases 0.000 description 1
• MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
• GLDSKRNGVVYJAB-DQSJHHFOSA-N hesperadin Chemical compound C12=CC(NS(=O)(=O)CC)=CC=C2NC(=O)\C1=C(C=1C=CC=CC=1)/NC(C=C1)=CC=C1CN1CCCCC1 GLDSKRNGVVYJAB-DQSJHHFOSA-N 0.000 description 1
• FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
• 230000006195 histone acetylation Effects 0.000 description 1
• 238000009474 hot melt extrusion Methods 0.000 description 1
• 102000055590 human KDR Human genes 0.000 description 1
• XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
• ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
• 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
• 230000000148 hypercalcaemia Effects 0.000 description 1
• 208000030915 hypercalcemia disease Diseases 0.000 description 1
• 230000001969 hypertrophic effect Effects 0.000 description 1
• 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 1
• TWSOHFLAODTOON-UHFFFAOYSA-N imidazolidine thiolane Chemical compound N1CNCC1.S1CCCC1 TWSOHFLAODTOON-UHFFFAOYSA-N 0.000 description 1
• 125000002883 imidazolyl group Chemical group 0.000 description 1
• 230000002519 immonomodulatory effect Effects 0.000 description 1
• 229940125721 immunosuppressive agent Drugs 0.000 description 1
• 239000003018 immunosuppressive agent Substances 0.000 description 1
• 230000001771 impaired effect Effects 0.000 description 1
• 238000000338 in vitro Methods 0.000 description 1
• 238000000099 in vitro assay Methods 0.000 description 1
• 238000001727 in vivo Methods 0.000 description 1
• 238000011065 in-situ storage Methods 0.000 description 1
• PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
• RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
• 150000002475 indoles Chemical class 0.000 description 1
• JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical compound C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 description 1
• 208000000509 infertility Diseases 0.000 description 1
• 230000036512 infertility Effects 0.000 description 1
• 231100000535 infertility Toxicity 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 239000007972 injectable composition Substances 0.000 description 1
• 229940102223 injectable solution Drugs 0.000 description 1
• 229940102213 injectable suspension Drugs 0.000 description 1
• 229940125396 insulin Drugs 0.000 description 1
• 230000031146 intracellular signal transduction Effects 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000007919 intrasynovial administration Methods 0.000 description 1
• 238000007913 intrathecal administration Methods 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 150000002500 ions Chemical class 0.000 description 1
• SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
• QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
• 210000001117 keloid Anatomy 0.000 description 1
• 210000002415 kinetochore Anatomy 0.000 description 1
• 235000010445 lecithin Nutrition 0.000 description 1
• 239000000787 lecithin Substances 0.000 description 1
• 229940067606 lecithin Drugs 0.000 description 1
• IOOMXAQUNPWDLL-UHFFFAOYSA-M lissamine rhodamine anion Chemical compound C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S([O-])(=O)=O)C=C1S([O-])(=O)=O IOOMXAQUNPWDLL-UHFFFAOYSA-M 0.000 description 1
• HINICOSKCHKZOG-UHFFFAOYSA-N lithium;1,2-difluorobenzene-6-ide Chemical compound [Li+].FC1=CC=C[C-]=C1F HINICOSKCHKZOG-UHFFFAOYSA-N 0.000 description 1
• KCTBOHUTRYYLJA-UHFFFAOYSA-N lithium;2h-furan-2-ide Chemical compound [Li+].C=1C=[C-]OC=1 KCTBOHUTRYYLJA-UHFFFAOYSA-N 0.000 description 1
• 210000004185 liver Anatomy 0.000 description 1
• 208000019423 liver disease Diseases 0.000 description 1
• 230000004807 localization Effects 0.000 description 1
• 239000006210 lotion Substances 0.000 description 1
• 210000001165 lymph node Anatomy 0.000 description 1
• 210000004324 lymphatic system Anatomy 0.000 description 1
• 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
• 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 1
• 239000011777 magnesium Substances 0.000 description 1
• 229910052749 magnesium Inorganic materials 0.000 description 1
• 239000000391 magnesium silicate Substances 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
• 235000019793 magnesium trisilicate Nutrition 0.000 description 1
• 229940099273 magnesium trisilicate Drugs 0.000 description 1
• 201000004792 malaria Diseases 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• 230000036210 malignancy Effects 0.000 description 1
• 230000003211 malignant effect Effects 0.000 description 1
• 238000001819 mass spectrum Methods 0.000 description 1
• 208000000516 mast-cell leukemia Diseases 0.000 description 1
• 208000008585 mastocytosis Diseases 0.000 description 1
• 238000005259 measurement Methods 0.000 description 1
• 239000002609 medium Substances 0.000 description 1
• 230000017346 meiosis I Effects 0.000 description 1
• 230000002175 menstrual effect Effects 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 230000004060 metabolic process Effects 0.000 description 1
• 239000002207 metabolite Substances 0.000 description 1
• 229910052751 metal Inorganic materials 0.000 description 1
• 239000002184 metal Chemical class 0.000 description 1
• 125000006525 methoxy ethyl amino group Chemical group [H]N(*)C([H])([H])C([H])([H])OC([H])([H])[H] 0.000 description 1
• 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
• 238000000386 microscopy Methods 0.000 description 1
• 210000004688 microtubule Anatomy 0.000 description 1
• 230000005012 migration Effects 0.000 description 1
• 238000013508 migration Methods 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• 230000000394 mitotic effect Effects 0.000 description 1
• 230000026232 mitotic prophase Effects 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• BDRTVPCFKSUHCJ-UHFFFAOYSA-N molecular hydrogen;potassium Chemical compound [K].[H][H] BDRTVPCFKSUHCJ-UHFFFAOYSA-N 0.000 description 1
• 239000002899 monoamine oxidase inhibitor Substances 0.000 description 1
• 125000005322 morpholin-1-yl group Chemical group 0.000 description 1
• 125000004312 morpholin-2-yl group Chemical group [H]N1C([H])([H])C([H])([H])OC([H])(*)C1([H])[H] 0.000 description 1
• 125000004572 morpholin-3-yl group Chemical group N1C(COCC1)* 0.000 description 1
• 239000012452 mother liquor Substances 0.000 description 1
• 230000004118 muscle contraction Effects 0.000 description 1
• 208000027531 mycobacterial infectious disease Diseases 0.000 description 1
• 229960004866 mycophenolate mofetil Drugs 0.000 description 1
• RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 1
• 230000002107 myocardial effect Effects 0.000 description 1
• HVOYZOQVDYHUPF-UHFFFAOYSA-N n,n',n'-trimethylethane-1,2-diamine Chemical compound CNCCN(C)C HVOYZOQVDYHUPF-UHFFFAOYSA-N 0.000 description 1
• ULWOJODHECIZAU-UHFFFAOYSA-N n,n-diethylpropan-2-amine Chemical compound CCN(CC)C(C)C ULWOJODHECIZAU-UHFFFAOYSA-N 0.000 description 1
• REPVNSJSTLRQEQ-UHFFFAOYSA-N n,n-dimethylacetamide;n,n-dimethylformamide Chemical compound CN(C)C=O.CN(C)C(C)=O REPVNSJSTLRQEQ-UHFFFAOYSA-N 0.000 description 1
• MCBRWEHADUHRIS-UHFFFAOYSA-N n-[2-[4-(4-methylpiperazin-1-yl)-6-[(5-methyl-1h-pyrazol-3-yl)amino]pyrimidin-2-yl]-1-benzofuran-5-yl]cyclopropanesulfonamide Chemical compound C1CN(C)CCN1C1=CC(NC2=NNC(C)=C2)=NC(C=2OC3=CC=C(NS(=O)(=O)C4CC4)C=C3C=2)=N1 MCBRWEHADUHRIS-UHFFFAOYSA-N 0.000 description 1
• SRDJUDHSQKYYBL-UHFFFAOYSA-N n-[2-[4-[(5-methyl-1h-pyrazol-3-yl)amino]-6-(oxan-4-ylamino)pyrimidin-2-yl]-1-benzofuran-5-yl]cyclopropanesulfonamide Chemical compound N1C(C)=CC(NC=2N=C(N=C(NC3CCOCC3)C=2)C=2OC3=CC=C(NS(=O)(=O)C4CC4)C=C3C=2)=N1 SRDJUDHSQKYYBL-UHFFFAOYSA-N 0.000 description 1
• LKPFBGKZCCBZDK-UHFFFAOYSA-N n-hydroxypiperidine Chemical compound ON1CCCCC1 LKPFBGKZCCBZDK-UHFFFAOYSA-N 0.000 description 1
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 238000005648 named reaction Methods 0.000 description 1
• KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
• 125000001624 naphthyl group Chemical group 0.000 description 1
• 239000007922 nasal spray Substances 0.000 description 1
• 210000000822 natural killer cell Anatomy 0.000 description 1
• 230000014399 negative regulation of angiogenesis Effects 0.000 description 1
• 230000006654 negative regulation of apoptotic process Effects 0.000 description 1
• 230000027498 negative regulation of mitosis Effects 0.000 description 1
• 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 description 1
• 239000003900 neurotrophic factor Substances 0.000 description 1
• 230000007935 neutral effect Effects 0.000 description 1
• 239000002547 new drug Substances 0.000 description 1
• 235000001968 nicotinic acid Nutrition 0.000 description 1
• 239000011664 nicotinic acid Substances 0.000 description 1
• 150000002823 nitrates Chemical class 0.000 description 1
• 229910017604 nitric acid Inorganic materials 0.000 description 1
• 231100000344 non-irritating Toxicity 0.000 description 1
• 239000012038 nucleophile Substances 0.000 description 1
• 239000002777 nucleoside Substances 0.000 description 1
• 239000002773 nucleotide Substances 0.000 description 1
• 125000003729 nucleotide group Chemical group 0.000 description 1
• GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
• ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
• 239000004006 olive oil Substances 0.000 description 1
• 235000008390 olive oil Nutrition 0.000 description 1
• 230000000771 oncological effect Effects 0.000 description 1
• 210000000287 oocyte Anatomy 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• 230000003204 osmotic effect Effects 0.000 description 1
• 230000002018 overexpression Effects 0.000 description 1
• 210000003101 oviduct Anatomy 0.000 description 1
• 125000001715 oxadiazolyl group Chemical group 0.000 description 1
• 125000004043 oxo group Chemical group O=* 0.000 description 1
• 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
• 229910052763 palladium Inorganic materials 0.000 description 1
• PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 230000001575 pathological effect Effects 0.000 description 1
• 239000008188 pellet Substances 0.000 description 1
• JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
• 239000003208 petroleum Substances 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• NHKJPPKXDNZFBJ-UHFFFAOYSA-N phenyllithium Chemical compound [Li]C1=CC=CC=C1 NHKJPPKXDNZFBJ-UHFFFAOYSA-N 0.000 description 1
• 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
• 150000003014 phosphoric acid esters Chemical class 0.000 description 1
• LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 1
• 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
• 229940075930 picrate Drugs 0.000 description 1
• OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
• 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 1
• 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
• 229950010765 pivalate Drugs 0.000 description 1
• IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
• 229910052697 platinum Inorganic materials 0.000 description 1
• 239000003880 polar aprotic solvent Substances 0.000 description 1
• 210000004508 polar body Anatomy 0.000 description 1
• 229920000058 polyacrylate Polymers 0.000 description 1
• 125000003367 polycyclic group Chemical group 0.000 description 1
• 229920000573 polyethylene Polymers 0.000 description 1
• 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
• 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
• 229920001451 polypropylene glycol Polymers 0.000 description 1
• 229920000136 polysorbate Polymers 0.000 description 1
• 229940113124 polysorbate 60 Drugs 0.000 description 1
• 229920002223 polystyrene Polymers 0.000 description 1
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
• 239000011591 potassium Substances 0.000 description 1
• 239000004302 potassium sorbate Substances 0.000 description 1
• 235000010241 potassium sorbate Nutrition 0.000 description 1
• 229940069338 potassium sorbate Drugs 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• 239000002243 precursor Substances 0.000 description 1
• 208000037821 progressive disease Diseases 0.000 description 1
• 230000006785 proliferative vitreoretinopathy Effects 0.000 description 1
• 230000031877 prophase Effects 0.000 description 1
• 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
• 235000013772 propylene glycol Nutrition 0.000 description 1
• 201000001514 prostate carcinoma Diseases 0.000 description 1
• 229950008679 protamine sulfate Drugs 0.000 description 1
• 230000009822 protein phosphorylation Effects 0.000 description 1
• 238000001243 protein synthesis Methods 0.000 description 1
• 125000003373 pyrazinyl group Chemical group 0.000 description 1
• 125000004289 pyrazol-3-yl group Chemical group [H]N1N=C(*)C([H])=C1[H] 0.000 description 1
• USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 1
• 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 1
• 125000002098 pyridazinyl group Chemical group 0.000 description 1
• 125000004076 pyridyl group Chemical group 0.000 description 1
• 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
• FVLAYJRLBLHIPV-UHFFFAOYSA-N pyrimidin-5-amine Chemical compound NC1=CN=CN=C1 FVLAYJRLBLHIPV-UHFFFAOYSA-N 0.000 description 1
• JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
• 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
• 230000005855 radiation Effects 0.000 description 1
• ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
• 230000008707 rearrangement Effects 0.000 description 1
• 229940100618 rectal suppository Drugs 0.000 description 1
• 239000006215 rectal suppository Substances 0.000 description 1
• 238000006268 reductive amination reaction Methods 0.000 description 1
• 229960004181 riluzole Drugs 0.000 description 1
• YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
• 229960001860 salicylate Drugs 0.000 description 1
• 210000003296 saliva Anatomy 0.000 description 1
• 201000007416 salivary gland adenoid cystic carcinoma Diseases 0.000 description 1
• 239000000523 sample Substances 0.000 description 1
• 231100000241 scar Toxicity 0.000 description 1
• 230000037387 scars Effects 0.000 description 1
• 208000011571 secondary malignant neoplasm Diseases 0.000 description 1
• 230000028327 secretion Effects 0.000 description 1
• 210000000582 semen Anatomy 0.000 description 1
• 230000019491 signal transduction Effects 0.000 description 1
• 230000011664 signaling Effects 0.000 description 1
• 150000004760 silicates Chemical class 0.000 description 1
• QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
• 229960002930 sirolimus Drugs 0.000 description 1
• 150000003384 small molecules Chemical class 0.000 description 1
• AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
• QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
• 229910052938 sodium sulfate Inorganic materials 0.000 description 1
• 235000011152 sodium sulphate Nutrition 0.000 description 1
• 239000006104 solid solution Substances 0.000 description 1
• 230000003381 solubilizing effect Effects 0.000 description 1
• 239000004334 sorbic acid Substances 0.000 description 1
• 235000010199 sorbic acid Nutrition 0.000 description 1
• 229940075582 sorbic acid Drugs 0.000 description 1
• 239000001587 sorbitan monostearate Substances 0.000 description 1
• 235000011076 sorbitan monostearate Nutrition 0.000 description 1
• 229940035048 sorbitan monostearate Drugs 0.000 description 1
• 241000894007 species Species 0.000 description 1
• 210000000952 spleen Anatomy 0.000 description 1
• 238000001694 spray drying Methods 0.000 description 1
• 239000007858 starting material Substances 0.000 description 1
• 230000004936 stimulating effect Effects 0.000 description 1
• 201000011549 stomach cancer Diseases 0.000 description 1
• 230000004960 subcellular localization Effects 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
• 150000003871 sulfonates Chemical class 0.000 description 1
• YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
• 238000013268 sustained release Methods 0.000 description 1
• 239000012730 sustained-release form Substances 0.000 description 1
• 239000003765 sweetening agent Substances 0.000 description 1
• 238000002636 symptomatic treatment Methods 0.000 description 1
• 238000010189 synthetic method Methods 0.000 description 1
• 229960001967 tacrolimus Drugs 0.000 description 1
• QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
• 239000008399 tap water Substances 0.000 description 1
• 235000020679 tap water Nutrition 0.000 description 1
• 229940095064 tartrate Drugs 0.000 description 1
• MHXBHWLGRWOABW-UHFFFAOYSA-N tetradecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC MHXBHWLGRWOABW-UHFFFAOYSA-N 0.000 description 1
• 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
• 230000001225 therapeutic effect Effects 0.000 description 1
• 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
• 229930192474 thiophene Natural products 0.000 description 1
• ZWYDDDAMNQQZHD-UHFFFAOYSA-L titanium(ii) chloride Chemical compound [Cl-].[Cl-].[Ti+2] ZWYDDDAMNQQZHD-UHFFFAOYSA-L 0.000 description 1
• JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
• 238000011200 topical administration Methods 0.000 description 1
• 239000012049 topical pharmaceutical composition Substances 0.000 description 1
• UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
• 229960000303 topotecan Drugs 0.000 description 1
• 238000012546 transfer Methods 0.000 description 1
• 230000009466 transformation Effects 0.000 description 1
• 238000000844 transformation Methods 0.000 description 1
• 230000014616 translation Effects 0.000 description 1
• 238000011269 treatment regimen Methods 0.000 description 1
• 125000001425 triazolyl group Chemical group 0.000 description 1
• YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
• 229960004319 trichloroacetic acid Drugs 0.000 description 1
• 230000001960 triggered effect Effects 0.000 description 1
• 239000001226 triphosphate Substances 0.000 description 1
• 235000011178 triphosphate Nutrition 0.000 description 1
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
• 229910052722 tritium Inorganic materials 0.000 description 1
• ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
• 210000003932 urinary bladder Anatomy 0.000 description 1
• 210000002700 urine Anatomy 0.000 description 1
• 210000004291 uterus Anatomy 0.000 description 1
• 238000003828 vacuum filtration Methods 0.000 description 1
• 210000001215 vagina Anatomy 0.000 description 1
• 235000013311 vegetables Nutrition 0.000 description 1
• 229960004528 vincristine Drugs 0.000 description 1
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
• 230000003612 virological effect Effects 0.000 description 1
• 239000001993 wax Substances 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1
• 239000003871 white petrolatum Substances 0.000 description 1
• 210000002268 wool Anatomy 0.000 description 1
• 150000003751 zinc Chemical class 0.000 description 1